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1. INTRODUCTION 
Viruses are obligate intracellular parasites that hijack the host cell’s machinery 
to replicate. They exhibit many different shapes and are present wherever there 
are cells to infect. In fact, viruses are the most common biological units on 
Earth, outnumbering all other types combined. One main motivation for the 
study of viruses is that they cause many important infectious diseases, and some 
have been shown to contribute to the development of certain forms of cancer.  
Alphaviruses are no exception, as this genus includes viruses pathogenic to a 
wide variety of animals, including humans, causing a spectrum of diseases that 
ranges from unpleasant cold-like illness and arthritis to fatal encephalitis. Thus, 
the study of alphaviruses is an important field of investigation. A well-studied 
virus belonging to this genus is Semliki Forest virus (SFV). Laboratory strains 
of SFV are relatively harmless to humans and thus have been utilized 
extensively in genetic engineering. They also provide a well-characterized 
model system to investigate the pathogenesis of viral encephalitis. 
Alphavirus infection consists of an intricate interplay between the virus and 
the host. The goal of the host is to eradicate the virus and survive, while the 
goal of the virus is to continue to proliferate regardless of the cost to the host 
cell. Importantly, viral infection is not equivalent to virus-induced pathogenesis. 
Alphaviruses can infect a large variety of organisms (from nematodes to 
humans), but they cause diseases in only a few of their hosts. Investigators have 
sought to identify the features of viral virulence and host defense that determine 
the outcome of infection. Different strains of SFV, which are designated as 
virulent or avirulent according to their effects in adult mice, have provided 
insight regarding this topic.   
The aim of the present study was to assess the determinants and mechanism(s) 
underlying the contrasting neurovirulence of different strains of SFV. New 
molecular clones were constructed and used to identify viral factors that 
contribute to infection. The ability of SFV to enter the central nervous system 
was found to depend on charged amino acid residues on the surface of viral 
glycoprotein E2. The importance of nonstructural protein 3 and the rate of 
nonstructural polyprotein processing in SFV neurovirulence were also 
investigated. Furthermore, we briefly reviewed the importance of cellular host 
factors and defense systems that play a role in alphavirus infection.  
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2. REVIEW OF LITERATURE 
The Baltimore classification system places viruses into one of seven groups based 
on their genome (DNA, RNA) and method of replication. Single-stranded RNA 
viruses are classified according to the polarity of their genomic RNA as positive-
strand and negative-strand viruses (group IV and V, respectively) (1). Positive-
strand RNA viruses contain messenger-sense RNA in their virions, they represent 
more than one-third of known virus genera and include many important human, 
animal, and plant pathogens. Among the members of this group is the family 
Togaviridae, which consists of two virus genera: the Alphavirus and the 
Rubivirus. The sole member of the Rubivirus genus is the rubella virus, an 
airborne virus that only infects humans, causing a disease referred to as “three-
day measles”. The Alphavirus genus currently consists of 31 recognized species, 
including several important human and animal pathogens (2, 3).  
 
 
2.1. Alphaviruses 
Viruses in the genus Alphavirus (hereafter referred to as alphaviruses) are 
mostly arthropod-borne and are transmitted in nature in a classical arbovirus 
transmission cycle. Mosquitoes typically of the Aedes and Culex genera carry 
them between vertebrate reservoir hosts, including birds and rodents. In insects, 
alphavirus infection is persistent and lifelong and is assumed to be asymptomatic. 
In vertebrates, the duration of infection is usually short and ends with the death 
of the infected host or clearance of the virus by the immune system. These 
differences are recapitulated in the corresponding cell culture systems (4).  
Alphaviruses that infect birds and mammals have historically been divided 
into Old World and New World alphaviruses. Old World alphaviruses, including 
Chikungunya (CHIKV), Sindbis (SINV), Ross River (RRV), and Semliki Forest 
virus (SFV), are found in Europe, Asia, Africa, and Australia. The acute phase of 
disease associated with these viruses is characterized by fever, chills, headache, 
myalgia, arthralgia, diarrhea, vomiting, and rash. While the mortality associated 
with these viruses is low, the diseases associated with some of the Old World 
alphaviruses can be debilitating, with clinical complications that persist from 
months to years (5). The recent CHIKV epidemics in Southeast Asia, India, 
Indian Ocean territories, and Caribbean countries have severely affected millions 
of people (6). CHIKV transmission has also been reported in Europe (Italy, 
France and Croatia) and in 45 countries or territories throughout the Americas (7). 
Consequently, great public attention has been directed towards alphaviruses. 
New World alphaviruses, including Eastern equine encephalitis (EEEV), 
Venezuelan equine encephalitis (VEEV), and Western equine encephalitis 
virus, are found in North and South America. Symptoms similar to those 
described above may occur during the acute phase of infection, but, as sug-
gested by their names, these viruses can cause acute encephalitis in humans and 
12 
domestic animals. Among the New World alphaviruses, EEEV is particularly 
virulent in humans, with an associated mortality of 50–75% of symptomatic 
cases. Due to their potential for emergence/reemergence or use as agents of bio-
terrorism, EEEV, VEEV, and CHIKV have been declared high priority patho-
gens by the National Institutes of Health. However, because alphavirus infec-
tions were not considered to be medically significant until recently, no effective 
antiviral drugs or licensed vaccines are available for human use against any 
alphavirus (4, 8–10). 
Historically, the two most studied members of the Alphavirus genus have 
been SFV and SINV. Both of these viruses grow to high titers in cell culture, 
infect cells from a wide range of invertebrate and vertebrate organisms, and are 
available as laboratory strains that are not typically associated with serious 
human illness, making them good model systems. For historical reasons, SFV 
has been mainly studied in Europe, whereas the primary model of alphavirus 
research in the USA has been SINV. The availability of complementary DNA 
(cDNA) clones for both of these viruses (11, 12) has made them a useful tool to 
study viral replication strategies and virus-host relationships. Studies 
investigating SFV and SINV have shed light on many aspects of the alphavirus 
infection cycle and have helped to elucidate the basic characteristics of several 
cellular processes. SFV was the first virus that was shown to enter cells via 
endocytosis and membrane fusion (13). In addition to tissue culture, SFV and 
SINV have been advantageous for the investigation of viral infection at the 
organism level using mice and rats, making them good models of viral 
pathogenicity.  
 
 
2.2. Virion  
Alphavirus virions are enveloped spherical particles that are 65–70 nm in 
diameter. Among enveloped virions, they have an extremely regular structure. 
The single-stranded positive-sense RNA genome is surrounded by 240 copies of 
capsid protein that is arranged in a T=4 lattice forming the icosahedral 
nucleocapsid (Fig. 1A) (14). The N-terminal part of the capsid protein is rich in 
positively charged amino acid residues and is presumed to bind to the genomic 
RNA. The nucleocapsid is enveloped by the host-derived lipid bilayer, which is 
enriched with cholesterol and sphingolipids and embedded with the envelope 
glycoproteins E1 and E2 (Fig. 1A). The two transmembrane glycoproteins E1 
and E2 interact to form 240 rigid heterodimers. For CHIKV, the 3D structures 
of these proteins and that of their dimer have been resolved; this information, 
together with cryo-electron microscopy data, has resulted in a high-resolution 
structure of alphavirus virions (15). Three E1-E2 dimers in turn form 80 spike 
complexes (16). In addition to E1 and E2, lower numbers of smaller proteins 
(E3, 6K and TransFrame (TF)) are also present in alphavirus virions; however, 
the abundance of these proteins differs in different alphaviruses. The E2 protein 
13 
mediates binding of alphavirus virions to the host cell and is necessary for 
virion formation because it interacts with the capsid protein (see 2.4.1 and 
2.4.5) (17). E1 mediates fusion of the viral and host cell membranes during 
entry (18). E3, 6K and TF are important for regulating spike assembly and are 
necessary for efficient budding of the virus (19, 20).  
 
 
Figure 1. Alphavirus virion and structural proteins. A. The alphavirus virion 
consists of a nucleocapsid surrounded by a lipid bilayer. The nucleocapsid is composed 
of a positive-sense single-stranded RNA genome (black) and capsid proteins (pink). The 
lipid bilayer (grey) is embedded with heterodimers of viral glycoproteins E1 and E2 
(blue and green). B. Arrangement of structural proteins in cellular membranes. The 
schematic representation of polypeptide E2 shows domains A, B, and C. The β-ribbon 
connector between domains A, B, and C is depicted in black. 
 
The E2 protein has a C-terminal transmembrane helix followed by a cyto-
plasmic domain, which contacts the nucleocapsid (Fig. 1B). This interaction is 
important for the correct assembly and budding of progeny viruses from the 
plasma membrane of infected cells (21). The ectodomain of E2 consists of three 
immunoglobulin-fold domains termed A, B, and C (Fig. 1B). The presence of 
immunoglobulin folds in E2 is consistent with its function as a cell receptor 
binding protein. Domain B is at the distal end of the protein to the membrane 
and domain C is oriented towards the viral membrane. Domain A, the putative 
receptor-binding domain, is located at the center. In the virion, the E2-E1 
heterodimer is oriented such that domains A and B are exposed at the top of the 
spike and situated at the center and at the periphery, respectively. In the mature 
virus, domain B covers the fusion loop in the E1 protein. In the linear structure, 
domain B is connected to domains A and C by long connecting linker peptides 
(the “β-ribbon connector”) (Fig. 1B). An acid-sensitive region in the E2 β-ribbon 
becomes disordered in the low pH conditions that arise during endosome 
maturation. This structural transition is required for the virus to become 
fusogenic (see 2.4.1) (15, 22, 23). 
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2.3. Genome organization 
The genomic RNA (also referred to as 42S RNA for SFV and 49S RNA for 
SINV) of the typical alphavirus is an approximately 11.5–11.8 kb long single-
stranded RNA molecule with a 5’ cap0 structure and a 3’ poly(A) tail (Fig. 2) (2). 
The genome has two open reading frames (ORF). The 5’ two-thirds of the 
genome constitutes the first ORF, which is translated directly from genomic RNA 
and encodes the precursor of the nonstructural (ns) proteins required for RNA 
synthesis. In the majority of alphaviruses, this region contains a leaky in-frame 
opal stop codon at the junction of nsP3 and nsP4 (Fig. 2); hence, two polyproteins 
(designated P123 and P1234) are synthesized (2). The 3’ one-third of the genome 
encodes the structural proteins that function in the assembly of new virus particles 
and in the attachment and entry of the virus into new cells. The second ORF is 
expressed through the production of a subgenomic mRNA (sgRNA, also referred 
to as 26S RNA in SFV) from an internal promoter in the negative-strand RNA 
replication intermediate (24). The sequence of the 26S RNA overlaps with the 
last one-third of the 42S RNA. The sgRNAs that are synthesized during 
replication also have 5’ cap0 structures and 3’ poly(A) tails (2).  
The alphavirus genome contains three untranslated regions (UTRs); one 
occurs at the 5’ end, one is at the 3’ end, and one is at the junction region 
between the ns and the structural ORFs (Fig. 2). All of the UTRs contain cis-
acting elements called conserved sequence elements (CSEs) that are important 
for replication and transcription of the virus genome (2, 25).  
The 5’ end of the genome, or its complement in the 3’ end of the negative 
strand, contains two CSEs (Fig. 2). A conserved stem-loop structure (CSE1) in 
the 5’ UTR is thought to function as a promoter to synthesize genomic RNA 
from the negative strand and as a co-promoter to synthesize the negative strand 
from the positive strand template (26). Interestingly, the secondary structure of 
this region also prevents recognition of the cap0 structure by cellular IFIT1 
protein (interferon (IFN)-induced protein with tetratricopeptide repeats) (27). 
Slightly downstream from the CSE1, in the nsP1-coding region, is the 51-
nucleotide CSE2, which forms two stem-loop structures. Both the sequence and 
the structure of the loops are important for CSE2 to function as a transcriptional 
enhancer (28). Additionally, CSE2 has been shown to be crucial for alphavirus 
replication in insect cells, because mutations in the 51-nucleotide element have 
a greater effect in the mosquito host than in the mammalian host (29). The third 
CSE is located in the region encoding the C-terminus of nsP4 (Fig. 2) (30). 
CSE3 forms the conserved part of the sg promoter, which is a cis-acting region 
spanning from position –98 to position +14 with respect to the sgRNA 
transcription start site. The minimal length of the sg promoter in SINV and most 
alphaviruses is 24 nucleotides (31); however, it is considerably longer in several 
SFV stains (32). The final 19 nucleotides preceding the 3’ poly(A) tail comprise 
the CSE4, the sequence of which is highly conserved across the genus and 
which contains the core negative-strand promoter. The 3’ 13 nucleotides of the 
CSE4 and a poly(A) tail of at least 11 residues were found to be the most 
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critical for negative strand RNA synthesis, which is initiated at the C-residue 
immediately upstream of the poly(A) sequence (33). 
 
 
Figure 2. Alphavirus genome organization with the encoded proteins and cis-
acting sequences. The alphavirus genome is a single-stranded positive sense RNA with 
a 5’ cap0 structure and a 3’ poly(A) tail. The 5’ two-thirds encodes for ns proteins re-
quired for replication and transcription of viral RNA, and the 3’ one-third encodes for 
structural proteins necessary for virion formation. The precursor of the ns proteins is 
translated directly from the genome, whereas the structural proteins are expressed from 
sgRNA. The conserved sequence elements (CSEs) are indicated in their relative positions 
in the genomic RNA. RSEs stands for repeat sequence elements, URE means U-rich 
element. The cis-acting element labels are color coded to indicate whether RNA 
secondary structure, primary nucleotide sequence, or both, is conserved. The indicated in-
frame opal stop codon is present in the genomes of a number of alphaviruses. In most 
SFV strains and some strains of CHIKV and ONNV, this codon is replaced by an arginine 
codon. However, a few strains of SFV, including A7(74), contain the opal stop codon.  
The genome of alphaviruses also contains cis-acting elements that are needed 
for functions other than RNA replication and transcription. First, the region 
encoding ns proteins contains a packaging signal for the alphavirus genome. 
The signal is located in the region encoding the nsP1 protein in SINV and 
encephalitic viruses (34, 35). In SFV and other members of the SFV clade, the 
packaging signal is located in the nsP2-encoding region (Fig. 2) (36). Second, 
there is a stem-loop structure immediately adjacent to the opal stop codon that 
is present at the end of the sequence encoding the nsP3 protein in SINV, VEEV, 
and many other alphaviruses (Fig. 2). This structure enhances readthrough of 
the stop codon by as much as tenfold, leading to more efficient generation of 
the full-length P1234 polyprotein (37). Third, the 5’ end of the capsid gene of 
SFV and SINV contains a translational enhancer that is needed for the efficient 
synthesis of structural proteins during later infection (Fig. 2) (38). Fourth, the 
sequence encoding the 6K protein contains a –1 ribosomal frameshift signal that 
results in the synthesis of the structural TF protein (Fig. 2) (39). Finally, there 
are elements in the 3’ UTR that interact with host factors during later infection 
and confer resistance to deadenylation. SINV and VEEV rely on a U-rich 
element (URE) for binding host factors, whereas other members of the genus 
depend on the repeat sequence elements (RSEs) (40-42).  
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2.4. Alphavirus infection cycle 
2.4.1. Virus entry 
The first step in alphavirus infection involves binding of the virus to a host cell 
receptor. The viral E2 glycoprotein is an antireceptor primarily responsible for 
virion binding to the cell surface (43), although the E1 protein may also play a 
role in receptor engagement. Alphaviruses have a very broad host range and 
replicate in cells from various tissues within their hosts. This suggests that 
either a considerably conserved receptor is utilized for attachment or multiple  
 
 
 
Figure 3. Alphavirus infection cycle. The alphavirus virion enters the host cell by 
clathrin-dependent endocytosis. The fusion of endosome and viral membranes follows, 
and the viral genomic RNA is released into cytoplasm. The genomic RNA is immediately 
translated into ns polyprotein P1234 (grey), which is proteolytically processed and 
forms first the negative-strand and then positive-strand replicase. The negative-strand 
replicase produces negative-strand RNA serving as a template for new genomic and 
sgRNAs. The sgRNA drives the expression of structural polyprotein, which is co- and 
posttranslationally processed. First, the capsid protein (pink) is released, and it associates 
with newly synthesized genomic RNA to form the nucleocapsid. Maturation of 
glycoproteins occurs in the endoplasmic reticulum (ER) and Golgi compartment. Mature 
glycoproteins (blue and green) are transported to the plasma membrane. The nucleocapsid 
associates with glycoproteins at the plasma membrane and virion budding occurs. 
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cellular receptors are employed for virus binding. Specific host receptors are 
known only for few alphaviruses and even they vary between different 
alphavirus species. The laminin receptor has been shown to mediate the entry of 
SINV into mammalian cells and the entry of VEEV into mosquito cells (44, 
45). Recently, the natural resistance-associated macrophage protein (NRAMP) 
(a divalent metal ion transporter) was shown to mediate SINV, but not RRV, 
entry into both mammalian and insect cells (46). To date, no host cell receptor 
has been identified for SFV. In addition to proteinaceous receptors, nonprotein 
attachment factors, including heparan sulfate (HS), might be utilized by 
alphaviruses to aid initial binding to the host cell surface (17). 
Cell-bound virions enter host cells via clathrin-dependent endocytosis (Fig. 3) 
(47). As the virion-containing endosomal vesicles mature, the pH becomes 
acidic, triggering conformational rearrangements of the structural proteins. The 
E1-E2 heterodimers are destabilized, and the previously hidden hydrophobic 
fusion loop in E1 is exposed (23). The fusion peptide is inserted into the 
endosomal membrane and E1 heterotrimers are formed, which in turn leads to 
the fusion of the virion envelope and endosomal membrane and the release of 
the nucleocapsid into the cytoplasm (22, 48, 49). The released nucleocapsid is 
disassembled by ribosomes, and the viral RNA genome is liberated into the 
cytoplasm (50). 
 
2.4.2. RNA replication  
Alphavirus replication occurs exclusively in the cytoplasm of the infected cell. 
The synthesis of viral RNA requires all four ns proteins, both individually, and 
in the context of ns polyprotein precursors. As for all positive-strand RNA 
viruses, the genome replication occurs via the synthesis of a negative-strand RNA 
intermediate. The first step after nucleocapsid disassembly is the translation of 
viral genomic RNA by host cell ribosomes to produce the ns polyprotein (Fig. 3). 
The majority of the translation events, as much as ~80–90%, produce the P123 
polyprotein; readthrough of the opal stop codon at the junction of nsP3 and 
nsP4 results in the production of the P1234 polyprotein (51, 52). Some isolates 
of SFV, CHIKV and ONNV carry an arginine codon instead of the opal stop 
codon; accordingly, only P1234 is produced by these viruses (53). The syn-
thesized ns polyproteins are autocatalytically cleaved by the protease activity of 
nsP2 into processing intermediates and thereafter into individual ns proteins in a 
precisely and temporally regulated manner (54, 55). The P123 polyprotein lacks 
any intrinsic RNA-synthetic activity due to the absence of the viral RNA- 
dependent RNA polymerase (RdRp), nsP4 protein. Similarly, the P1234 form of 
the polyprotein is incapable of RNA synthesis until proteolytic processing 
releases the nsP4 component of the polyprotein (56).  
The full-length polyprotein P1234 cleaves itself in cis, yielding P123 and 
nsP4 (Fig. 4), which form the early replicase (Fig. 3). This P123/nsP4 complex 
uses genomic RNA as a template to produce negative-strand RNA (Fig. 3), 
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which, together with the genomic RNA, forms a double-stranded RNA 
(dsRNA) intermediate. The synthesis of negative-strand RNA occurs early 
during infection and is rapidly downregulated as the infection proceeds. The 
early replicase is short-lived; existing data indicate that an individual P123/nsP4 
complex may synthesize as few as a single negative-strand RNA molecule 
before undergoing further processing (56–58). The further cleavage of P123 
polyprotein occurs in cis and results in the liberation of nsP1 and the formation 
of the nsP1/P23/nsP4 complex (Fig. 4), which is capable of producing both 
negative and positive-strand RNAs (57, 59). However, the P23 intermediate is 
exceptionally short-lived, as it can only be detected following the mutation of 
the 2/3 cleavage site (60). Therefore, during wild type (wt) virus infection, P23 
is quickly processed in trans into nsP2 and nsP3 (Fig. 4), which, together with 
nsP4 and nsP1, form the positive-strand replicase. The nsP1/nsP2/nsP3/nsP4 
complex uses the previously synthesized negative-strand as a template to 
synthesize new positive-strand genomic and sgRNAs (Fig. 3) (54, 56). Re-
gulation of the synthesis of the two positive-sense RNAs depends on nsP4, 
because distinct sites in nsP4 have been shown to bind the two promoters in the 
negative-strand RNA (61-63). The effects of some mutations in nsP2 imply that 
nsP2 may also act as a transcription factor that associates with the sg promoter 
and recruits the RNA synthesis complex (64, 65). The synthesis of positive-
strand RNA continues at a maximal rate until the death of the infected cell. The 
produced sgRNAs serve as a template for the translation of viral structural 
proteins, while genomic RNAs interact with the capsid protein and are packed 
into new virions.  
 
Figure 4. Processing of ns polyprotein by the protease activity of the nsP2 region. 
Left, the processing of ns polyprotein at the early stages of infection. Initial cleavage 
occurs in cis and results in P123+nsP4, an early replicase that is active in negative 
strand RNA synthesis. Cleavage of P123 in cis yields nsP1+P23. The final cleavage of 
P23 occurs in trans, and the resultant late replicase is active only in the synthesis of 
genomic and sgRNAs. Right, processing order at the late stages of infection. Because 
the first cleavage of P1234 occurs between nsP2 and nsP3, there is no formation of early 
replicase (P123 + nsP4) and, therefore, no synthesis of negative strands. Although P12 
and P34 are subsequently processed into mature ns proteins, they do not form the RC. 
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Cleavage of the 2/3 site serves as an important temporal regulatory step in the 
replication and infection cycle. It transforms the viral replicase into its late form 
and prevents the subsequent synthesis of negative-strand RNAs. During the late 
stage of infection, the amount of free (not included in replicase complexes 
(RCs)) cytoplasmic nsP2 increases, leading to the rapid in trans cleavage of the 
2/3 site in newly synthesized ns polyproteins. This generates P12 and P34 
polyproteins (Fig. 4), which are incapable of forming new RCs. This cleavage, 
therefore, prevents the production of P1234 and P123; the formation of new 
RCs ceases, and the synthesis of negative-strand RNAs is switched off (66). 
However, the RCs that have already formed are stable and continue to 
synthesize positive-sense RNAs until the end of the infection cycle. 
 
2.4.3. Sites of replication 
Alphaviruses replicate their genomes in association with modified intracellular 
membranes. They induce the rearrangement of host membranes into cyto-
plasmic structures known as type I cytopathic vacuoles (CPV-Is) (67, 68) that 
represent the replication organelles of alphaviruses. CPV-Is are late endosomes 
and lysosomes with a diameter of 600–2000 nm. These vacuoles contain bulb-
shaped invaginations called spherules (~50 nm in diameter), which represent 
physical forms of alphavirus RCs and are the sites of viral RNA synthesis (69, 
70). The spherules first appear on the host plasma membrane; as the infection 
proceeds, the structures are internalized via endocytosis. Spherule-containing 
vesicles can fuse with one another and with lysosomes, and they are finally 
incorporated into CPV-Is (70-72). The significance of this process remains 
unknown, because blocking spherule internalization with different inhibitors 
has little or no effect on viral RNA synthesis (71, 72). The formation of these 
spherules requires ns proteins in the polyprotein stage as well as active RNA 
synthesis (71, 73). Each spherule appears to contain partly double-stranded 
replicative intermediate RNAs (74), but the exact copy number, stoichiometry, 
and locations of different nsPs within the alphavirus RCs remain unknown. In 
addition to viral proteins, several host proteins are bound to the spherules (71, 
72). It is likely that spherules are needed to protect dsRNA replication 
intermediates from host cell detection and disruption. Additionally, the membrane 
structures may act as scaffolds and effectively increase the concentration of 
replication factors at the sites of RNA synthesis. There are also considerable 
differences among alphaviruses with respect to the size and localization of 
CPV-Is. For instance, the CPV-Is of SFV are large structures that are located in 
perinuclear region, whereas the CPV-Is of CHIKV are generally smaller and, in 
most cases, localized close to the plasma membrane. Recently, the inter-
nalization of CPV-Is was shown to be associated with the ability of nsP3 of 
SFV to activate the phosphatidylinositol-3-kinase (PI3K)-Akt-mammalian target 
of Rapamycin (mTOR) pathway (75); however, the functional significance of 
these processes is currently unknown. 
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2.4.4. Synthesis of structural proteins 
Alphavirus structural proteins are translated from sgRNA in the form of  
C-p62(E3E2)-6K-E1 (Fig. 3) and p62(E3E2)-TF polyprotein precursors. The 
capsid protein is a serine protease and releases itself from the nascent precursor 
chain by autoproteolysis (Fig. 3) (76), thereby revealing an N-terminal signal 
sequence, which is used for p62 chain translocation to the endoplasmic 
reticulum (ER). In the ER, p62(E3E2)-6K-E1 polyprotein is cotranslationally 
glycosylated, palmitoylated, and cleaved by cellular proteases into p62, 6K, and 
E1. Glycosylated p62 and E1 form a stable heterodimer, which is transported 
through the secretory pathway to the Golgi complex (Fig. 3). In the Golgi, E3 is 
cleaved from p62-E1 by cellular furin protease, and the resulting E1-E2 
heterodimers are transported to the plasma membrane for virion assembly (Fig. 3) 
(77). For some alphaviruses, including SFV and VEEV, the released E3 protein 
is also incorporated into the virions (78, 79). However, in the majority of 
alphaviruses, including SINV, E3 is not present in the virions. It has been 
shown that binding of E3 to the spike complex protects E1 against low pH-
triggered conformational changes during virion biogenesis (80). The 6K protein 
is also incorporated into virions in smaller numbers (7–30 copies) and likely 
affects the interactions between E2 and E1 (17). During the translation of SFV 
structural proteins, a ribosomal frameshift occurs in the sequence encoding for 
6K with an efficiency of 10–18% and results in the production of TF protein 
(39). TF has been shown to be packed into virions, but its exact function(s) 
remains to be determined (20).  
 
2.4.5 Virion assembly and budding 
The formation of new virions begins with the assembly of nucleocapsids in the 
cytoplasm of the infected cell near the RCs. The encapsidation signal located in 
the region encoding nsP1 (or, in some viruses, nsP2) of the newly synthesized 
genomic RNA is recognized by the capsid protein, leading to the multi-
merization of the protein and the formation of an icosahedral nucleocapsid (Fig. 
3) (34, 36). The nucleocapsids diffuse or are transported to patches and extensions 
on the plasma membrane caused by the accumulation of envelope proteins. 
During budding, the nucleocapsids are bound by the cytoplasmic tails of E2 
glycoproteins, and the plasma membrane curves around the nucleocapsid. These 
interactions of viral envelope proteins with capsid protein are required to 
exclude other plasma membrane proteins from the sites of alphavirus budding 
(81). Finally, the lipoprotein envelope encloses the nucleocapsid, and the virion 
is released (Fig. 3). This process is facilitated by nsP1, which counteracts the 
antiviral effects of cellular tetherin (82). 
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2.5. Functions of individual ns proteins 
All four ns proteins are essential for alphavirus replication and have a multi-
domain structural organization (Fig. 5). Each protein has a unique and specific 
role in the viral infection cycle and virus-host interactions.  
NsP1 (for SFV: 537 aa, ∼60 kDa) has two main functions during alphavirus 
replication: it serves as a membrane anchor for the RC, and it is responsible for 
capping positive-strand RNAs. The N-terminal domain of nsP1 exhibits 
methyltransferase and guanylytransferase activities, which are involved in the 
capping process. The first reaction in cap synthesis is performed by nsP2, which 
removes the 5’ γ-phosphate of the nascent viral RNA through its RNA 
triphosphatase (RTPase) activity (83), whereas the subsequent two reactions are 
performed by nsP1. First, nsP1 acts as a guanine-7N-methyltransferase and 
transfers a methyl group from S-adenosyl-methionine to GTP. Second, nsP1 
guanylyltransferase activity allows it to form a covalent intermediate complex 
with 7-methyl-guanosine-5'-monophosphate (m7GMP) (84). The final step in 
cap synthesis is the transfer of m7GMP from nsP1 to the viral RNA molecule; 
this reaction is also most likely performed by nsP1 (85). The alphavirus mode 
of RNA capping stands in stark contrast to the eukaryotic capping mechanism, 
in which methylation occurs after the transfer of the guanylate moiety to the 
substrate RNA. 
The N-terminal domain is followed by regions that are necessary for the asso-
ciation of nsP1 (and replicase as whole) with host membranes: an amphipathic 
helix and site for posttranslational palmitoylation (86-89). The amphipathic 
helix, which is located between aa 245 and 264 in SFV (Fig. 5), mediates inter-
actions with membrane phospholipids. These interactions are required for the 
enzymatic activity of nsP1 of SFV (87). Point mutations in the amphipathic 
helix, which prevent binding to the membrane, are lethal to the virus (89). 
However, this effect may not be universal for all alphaviruses, because nsP1 of 
SINV retains enzymatic activity in the absence of phospholipids (90). 
Membrane binding is further strengthened by posttranslational palmitoylation of 
nsP1 cysteine residues at position 418–420 in SFV and 420 in SINV (Fig. 5). 
Nevertheless, palmitoylation is not essential for the enzymatic activities of 
nsP1, the formation of functional RCs, or the viability of the virus (91, 92). 
Despite lacking a phenotype in tissue culture models of infection, depal-
mitoylation mutants exhibit diminished pathogenesis in mice (86). Additionally, 
a mutation at position 538 (T538I) in nsP1 in the neurovirulent strain of SINV 
attenuates the virus and plays a key role in regulating viral neurovirulence (93).  
This attenuating mutation has been shown to modulate type I IFN induction, 
and an analogous mutation in RRV exerts a similar enhancing effect (94).  
NsP1 has been shown to interact with the N-terminus of the nsP4 protein, 
and this interaction is important for recognition of the negative-strand promoter 
and elongation of negative-strand RNA (95, 96). NsP1 is also responsible for 
the induction of filopodia-like structures on the surface of alphavirus-infected 
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cells (97, 98). The function of these filopodia-like structures, as well as the 
exact functional significance of palmitoylation, remain unknown. 
 
 
 
Figure 5. Modular organization of the ns polyprotein of alphaviruses. Arrows 
indicate sites of proteolytic cleavages within P1234 polyprotein. The N-terminal 
domain of nsP1 is responsible for methyltransferase and guanylytransferase (MT/GT) 
activities. An amphipathic helix (triple arrow) and posttranslational palmitoylation 
(corresponding site is indicated by an empty square) are necessary for the association of 
nsP1 protein to host membranes. RNA helicase and protease functions of nsP2 are 
assisted by the N-terminal domain (NTD). The N-terminal part of nsP2 has also NTPase 
and RTPase activities. Scissors indicate the location of the catalytic residues of the 
protease. nsP3 has three recognized domains: the macro domain, the zinc binding 
domain (ZBD), and the hypervariable domain (HVD). The phosphorylation sites are 
marked with a circled P. The N-terminal region of nsP4 is predicted to be unstructured, 
while the C-terminal part of nsP4 is homologous to the core of viral RNA-dependent 
RNA polymerases (RdRp). The catalytic residues of RdRp are indicated by an asterisk.  
 
The multi-domain protein nsP2 (for SFV: 798 aa, ∼90 kDa) exhibits four 
important enzymatic functions during viral infection, acting as an NTPase, an 
RNA helicase, an RNA triphosphatase, and a protease. It also possesses a 
variety of nonenzymatic functions. The N-terminal half of nsP2 contains 
domains that are required for its nucleoside triphosphatase (NTPase) and RNA-
5’-triphosphatase (RTPase) activities (83, 99). The RTPase activity of nsP2 is 
responsible for removing the γ-phosphate from the 5’ end of nascent positive-
sense RNA; it is therefore required for the nsP1-mediated capping reaction (83). 
NsP2 functions as an RNA helicase, likely by unwinding the RNA secondary 
structures that are formed during viral replication (100). The helicase activity of 
nsP2 is dependent on the NTPase activity, and unwinding has been shown to 
occur with a 5'–3' directional bias. All domains are required for the helicase 
activity of nsP2; helicase activity likely acts in coordination with the 
polymerase activity of nsP4 (101). Very recently, it was also demonstrated that 
nsP2 and nsP4 together regulate the replication fidelity of alphaviruses and that 
mutations in nsP2 allow the virus to overcome intracellular nucleotide depletion 
(102). The C-terminal region of nsP2 contains a papain-like protease domain 
that is responsible for processing the ns polyprotein (103). This protease activity 
is absolutely essential for the replication of the virus, and it has been shown to 
be functionally discrete from the nsP2 functions described above (104). NsP2 is 
capable of performing all of the cleavages required for the processing of P1234, 
this requires a catalytic cysteine residue at position 478 (Fig. 5) (55). Several 
criteria must be met to ensure that the proteolytic cleavages by nsP2 occur in a 
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particular order. The amino acid residues surrounding both sides of the scissile 
bond are important, but the structural placements of the nsP2 domains and other 
replicase proteins are also critical (66, 104-106). The 3D structures of the 
VEEV protease (107), SINV protease (108), and CHIKV protease (109) have 
been determined by X-ray crystallography. In all three proteases, the papain-
like domain is followed by an enzymatically nonfunctional methyltransferase-
like domain, which plays a role in the regulation of negative-strand RNA 
synthesis and the development of cellular cytopathic effects (110). It is also 
essential for the RNA helicase activity of nsP2 (101). Additionally, nsP2 has been 
shown to function as a transcription factor for sgRNA synthesis by recognizing 
the sg promoter (65, 111), and it has been proposed to mediate the binding of 
nsP4 to that promoter (61).  
NsP2 is the only ns protein of alphaviruses that has been shown to 
translocate to the nucleus. In SFV-infected cells, approximately 25% of nsP2s 
are associated with replication organelles, 25% are localized diffusely 
throughout the cytoplasm, and 50% are transported to the nucleus. While SINV 
nsP2 lacks a classical nuclear localization signal (NLS) (112), the nsP2 of SFV 
carries a pentapeptide PRRRV in its C-terminus (aa 647–651), which is 
assumed to function as an NLS (113). The mutation of arginine residues in this 
sequence to aspartate residues renders nsP2 completely cytoplasmic (114), 
though this effect is observed only at 37 °C and not at 28 °C (115). Regardless 
of the exact mechanism of entry, nuclear localization of nsP2 is required to turn 
off cellular transcription, which occurs via degradation of the catalytic subunit 
of cellular RNA polymerase II (116). Thus, the nuclear fraction of nsP2 is not 
directly required for viral replication but rather is responsible for the inhibition 
of cellular transcription. Mutations in nsP2 are also associated with reduced 
cytotoxicity, a lack of translational shutdown in host cells, and reduced viral 
pathogenicity in adult mice (114, 115, 117-119).   
The functions of nsP3 (for SFV: 482 aa, ~60 kDa) remain more elusive than 
those of the other ns proteins. nsP3 has three recognized domains: the macro 
domain, the zinc-binding domain (ZBD, also known as alphavirus unique 
domain (AUD)), and the hypervariable domain (HVD) (Fig. 5). The first 160 
amino acid residues in the N-terminus of nsP3 form a macro domain that is 
structurally conserved among alphaviruses, rubiviruses, hepeviruses and corona-
viruses (120). The macro domains have detectable homologs in a wide variety of 
bacteria, archaea, and eukaryotes (121); thus, it is assumed that they play 
fundamental roles in different organisms. The crystal structures of the macro 
domain of CHIKV, SINV, and VEEV have been determined. It has been found 
that the macro domains of CHIKV and VEEV exhibit weak ADP-ribose 1’’-
phosphate phosphatase activity (122, 123). However, the macro domain of SFV 
nsP3 lacks this activity, which suggests that this function is not needed for virus 
replication. The alphavirus macro domain has been shown to bind to RNA, 
polyADP-ribose, and, in some cases, ADP-ribose. RNA binding might be the 
true function of the nsP3 macro domain (122, 124). In addition, there is 
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evidence that the alphaviral macro domain is involved in one or more host 
protein interactions (125). Finally, the residues located at the C-terminus of the 
macro domain and/or in the region between the macro domain and the ZBD are 
essential for 2/3 site processing by nsP2 (105). 
The ZBD is located within the central portion of nsP3, a region that shares a 
strong sequence homology across the Alphavirus genus (2). This region was 
recently crystallized as part of the SINV P23 polyprotein and shown to contain 
a previously uncharacterized zinc coordination site (108). Genetic manipulation 
within the ZBD has resulted in defects in negative-strand and sgRNA synthesis, 
polyprotein processing and neurovirulence (126-128). Recent data indicate a 
functional interplay between the ZBD and the C-terminal HVD (75).  
The C-terminal region of nsP3 is intrinsically disordered. As implied by the 
name HVD, it exhibits different lengths and sequence compositions among the 
alphaviruses. Despite the lack of sequence conservation, the HVD contains 
sequence motifs that are present in a few or even in many alphaviruses. Thus, 
the HVD of the Old World alphaviruses SINV, SFV, and CHIKV exhibits a 
proline-rich motif that serves as a target site for the Src-homology 3 (SH3) 
domain of amphiphysin. Mutations in this proline-rich element result in slightly 
impaired viral RNA replication and significantly decreased virulence in mice 
(129). The HVD of VEEV nsP3 does not appear to have this motif (130). In the 
Old World alphaviruses SINV, SFV, and CHIKV, the HVD of nsP3 has also 
been shown to interact with the host protein Ras-GAP SH3-domain-binding 
protein (G3BP). This binding leads to the recruitment of G3BP into cytoplasmic 
foci, which in turn inhibits stress granule formation (131-133). This binding 
occurs via FGDF motifs that have only been characterized in Old World 
alphaviruses (134). In mosquito cells, the nsP3 of SFV and CHIKV binds to the 
mosquito homologue of G3BP proteins, called Rasputin (135, 136), potentially 
via the same FGDF motifs.  The nsP3 of New World alphaviruses lacks FGDF 
motifs, and hence, VEEV HVD does not bind to G3BP (130, 137). The HVD of 
VEEV nsP3 has been shown to contain many repeated elements that are 
indispensable for the replication of the virus in different cell types (other than 
BHK-21) and the formation of VEEV-specific cytoplasmic protein complexes 
(137). It should also be noted that interaction with G3BP proteins (and possibly 
with other cellular proteins) could serve multiple purposes. Thus, while the 
binding of nsP3 to G3BP proteins counteracts their antiviral activity (stress 
granule formation), G3BP proteins also possess proviral functions that may 
facilitate the switch from replicase protein translation to viral RNA replication 
(138). 
Based on our current understanding, nsP3 is the only alphavirus phospho-
protein; it undergoes phosphorylation at serine and threonine residues at the 
junction between the second and third domain (Fig. 5) (139, 140). In SFV, all 
16 of the identified phosphorylation sites (among which six of these residues 
account for the majority of nsP3 phosphorylation) occur in a short 50-amino 
acid region. SFV, with defective nsP3 phosphorylation exhibits a decreased rate 
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of RNA synthesis in cultured cells and greatly reduced pathogenicity in mice 
(140). In SINV, phosphorylation plays a role in negative-strand RNA synthesis 
(126). As observed for VEEV, the phosphorylation of the nsP3 HVD is 
important for viral replication in mosquito cells but not in cells of vertebrate 
origin (137). When expressed alone, nsP3 forms amorphous cytoplasmic non-
membranous granules (141). However, when it is expressed as part of the P123 
polyprotein, nsP3 is responsible for the relocalization of SFV replicase proteins 
from the plasma membrane into intracellular vesicles (66). This function is most 
likely also mediated by the HVD of nsP3, or more precisely by the region 
involved in the activation of the PI3K-Akt-mTOR pathway. Interestingly, in 
SFV, this region overlaps with the phosphorylation region. Nevertheless, 
activation of the PI3K-Akt-mTOR pathway does not depend on the 
phosphorylation of nsP3, indicating that the same region of HVD has several 
independent functions (75). 
All of the ns proteins are involved in some aspects of alphavirus RNA 
synthesis; however, nsP4 (for SFV: 614 aa, ∼70 kDa) is solely responsible for 
the RNA synthesis properties of the viral RC. The 3D structure of nsP4 is not 
known. However, the C-terminal sequence of the protein includes motifs that 
are typical of RdRp. Thus, it is very likely that nsP4 has a typical RdRp 3D 
structure with fingers, a palm containing the GDD motif, and thumb domain. 
The sequence of the ~100 N-terminal amino acid residues of nsP4 is conserved 
only among alphaviral nsP4 proteins (142-144).  
In comparison to the other ns proteins, nsP4 is scarce in infected cells, for 
two reasons. First, in most alphaviruses, including several SFV strains, the 
translation of nsP4 requires readthrough of an opal stop codon that is located at 
the end of the nsP3-encoding region (2). Second, the N-terminal amino acid in 
nsP4 is a conserved tyrosine that directs nsP4 to undergo rapid proteasomal 
degradation via the N-end rule pathway (145). In RCs, nsP4 appears to be 
stable, but the mechanism(s) responsible for this stabilization is not known. The 
N-terminal destabilizing tyrosine residue is essential for the polymerase activity 
of nsP4; accordingly, its replacement with a nonaromatic residue results in poor 
RNA replication (146).  
The expression and purification of functionally active recombinant full-
length nsP4 has historically been exceptionally difficult. In vitro experiments 
using N-terminal truncation mutants of nsP4, which are somewhat easier to 
produce, demonstrated terminal adenylyltransferase (TATase) activity. This 
function is likely required for the maintenance and repair of the poly(A) tail at 
the end of genomic and sgRNAs (144). The full-length nsP4 of SINV has been 
purified with an N-terminal SUMO tag. Full-length recombinant nsP4 exhibits 
TATase activity and is capable of de novo RNA synthetic activity. The latter 
ability, however, requires the addition of the other viral nsPs from a mammalian 
cell membrane fraction (143). Thus, although nsP4 is the sole viral protein with 
RdRp activity, viral replication occurs as a result of the sum of coordinated ns 
protein activity.  
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The nonconserved N-terminal region of nsP4 is disordered and is required 
for interactions with other ns proteins and viral RNA. Genetic evidence sug-
gests that the conserved N-terminal tyrosine interacts with nsP1 for negative-
strand synthesis (146). Studies have indicated that the N-terminal region plays 
an important role in recognizing the promoter at the 3’ end of the genomic 
strand for negative-strand synthesis (143). Crosslinking experiments have shown 
that nsP4 contains determinants that contact with sg and genomic promoters in 
the negative strand RNA. NsP4 alone recognizes the genomic promoter (61, 
62), but recognition of the sg promoter requires other nsPs, especially nsP2 
(147). Genetic evidence suggests that the N-terminal part of nsP4 may also be 
involved in interactions with host proteins (147). 
 
 
2.6. Virus-host interactions 
At the interface of viral infection and host response lies a complex network of 
regulated interactions. The host wants to eradicate the virus; the virus seeks to 
continue its own proliferation. Furthermore, alphaviruses have a limited coding 
capacity and thus rely extensively on host factors for successful infection and 
propagation. As a result, these viruses have developed mechanisms to hamper 
cellular antiviral processes while maintaining their own genome replication and 
virion production to spread in infected hosts.  
 
2.6.1. Shutdown of host cell transcription and translation 
Alphavirus infection of vertebrate cells causes the shutdown of host cell 
transcription and translation, but at the same time requires the synthesis of viral 
RNAs and proteins at a high rate. The shutdown of host macromolecule 
synthesis is essential for limiting the production of antiviral proteins, mainly 
type I IFNs, and hence diminishing the ability of the innate immune system to 
attenuate the infection. Old World and New World alphaviruses achieve this 
effect through the use of different proteins. 
For Old World alphaviruses, nsP2 mediates transcriptional shutdown via the 
degradation of Rpb1, a catalytic subunit of RNA polymerase II. In the presence 
of nsP2, Rbp1 is ubiquitinated and rapidly degraded, which in turn results in the 
cessation of host mRNA transcription (116). The New World alphaviruses 
utilize a different mechanism to shutdown cellular transcription. The VEEV 
capsid protein forms complexes with importin-α/β and the nuclear export 
receptor CRM1. These complexes accumulate in the nuclear pores of infected 
cells and inhibit the nucleocytoplasmic trafficking of proteins, eventually 
leading to transcriptional shutdown (148). In addition to inducing a general 
shutdown of host transcription, alphaviruses can also specifically target the 
expression of genes that are important for the innate immune response. SFV has 
been shown to specifically target the expression of type I IFNs in a manner that 
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differs from the virus-induced general shutdown of transcription (149). Viruses 
can also interfere with cellular antiviral signaling pathways: nsP2 of CHIKV 
has been shown to inhibit Jak-STAT signaling (150), and a similar phenomenon 
has also been observed for SINV (151).  
The shutdown of host cell translation in both groups is partially mediated by 
a cellular defense mechanism. The viral replication intermediate dsRNA is 
recognized by host dsRNA-activated protein kinase R (PKR), which leads to 
phosphorylation of the translation initiation factor eIF2 and inhibition of the 
initiation of cellular translation (152). Several alphaviruses, including SINV and 
SFV, have evolved a unique mechanism to bypass the requirement for eIF2 
through the presence of the translational enhancer (stable secondary structure) 
at the 5’ end of the capsid gene, which likely stalls ribosomes and directs them 
to the appropriate site to initiate translation (38, 153). 
PKR-dependent shutdown of translation is not the only mechanism 
employed by alphaviruses to achieve their goals. Another pathway that leads to 
eIF2 phosphorylation is the unfolded protein response in the ER (154, 155). 
Active synthesis of the alphavirus glycoproteins E1 and E2 in the ER likely 
exceeds the ER folding capacity, resulting in an unfolded proteins response. 
This process activates one of the major ER stress sensors, eIF2 kinase 3 
(PERK), which then phosphorylates eIF2 and thereby inhibits cellular 
translation (154). To overcome the effects of this inhibition, alphaviruses can 
suppress the unfolded protein response. In the case of CHIKV, this 
phenomenon is especially prominent, and viral nsP2 and/or nsP4 participate in 
this process (156, 157). 
A recent study has shown that for the inhibition of cellular protein synthesis 
to occur, viral RNA replication must take place at controlled levels, leading to 
the release of nuclear proteins into the cytoplasm (158). The shutdown of tran-
scription and translation of cellular mRNAs are independent events. Although 
the shutdown of host transcription is the more critical event for viral infection, 
the shutdown of host translation is also important. In general, mutations in nsP2 
disrupt viral shutdown of host cell translation, confirming the central role of this 
protein in this process (118). However, the mechanism(s) by which nsP2 
interferes with host cell translation is poorly understood. 
 
2.6.2. Host factors associated with alphavirus RCs 
The identification of relocalized host cell components and host cell components 
with altered quantities during viral infection is essential for understanding the 
interplay between the host and positive-strand RNA viruses. Recently, several 
different approaches have been used to tackle this question, including genome-
wide screens, whole-genome searches using siRNA libraries, and yeast two-
hybrid (Y2H) screens. These studies, in which several viruses were assessed, 
revealed hundreds of host-encoded proteins that interact with viral proteins and 
RNAs or otherwise participate in different stages of viral infection, including 
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RC assembly, RNA template recruitment, synthesis, and viral RNA stabili-
zation. Host proteins that negatively affect viral infection have also been identi-
fied (159, 160). Interestingly, the sets of host proteins that have been identified 
using different screens for the same virus show a tendency towards limited 
overlap. Hence, the list of cellular factors that are directly or indirectly involved 
in positive-strand RNA virus replication is long, and the mechanism of action is 
known for only a small number of proteins.  
Similarly, the list of host components that interact with the alphavirus nsPs 
and RNAs is slowly but steadily growing. Pull-down experiments using cells 
infected with SINV carrying GFP-tagged nsP3 (125, 131, 161), GFP-tagged 
nsP2 (162), and FLAG-tagged nsP4 (163) led to the identification of over-
lapping sets of co-precipitating cellular proteins, including G3BP1, G3BP2, 14-
3-3 proteins, poly(ADP-ribose) polymerase (PARP-1), and different hetero-
geneous ribonucleoproteins (hnRNPs). The overlap is likely due to precipitation 
of whole RCs and cellular proteins associated with any of their components, 
regardless of which ns protein was tagged. Thus, this approach provides limited 
information regarding the viral protein(s) that specifically interact with the 
identified host component. For example, G3BPs interact only with nsP3 (134); 
however, these proteins were also detected in experiments using tagged nsP2 
and nsP4 for the precipitation (162, 163).  
Very little is known about the functions of identified cellular factors in the 
viral infection cycle.  The interaction of G3BP with viral nsP3 leads to the 
recruitment of the former into cytoplasmic foci, which in turn inhibits stress 
granule formation that would otherwise inhibit viral infection (132, 134). 
Concomitantly, G3BPs also play a proviral role because their depletion hampers 
CHIKV infection (138). Viral nsP2 has also been found to co-purify with mul-
tiple ribosomal proteins, including ribosomal protein S6, and cellular filament 
components. Interactions between nsP2 proteins and ribosomal components 
have also been reported for VEEV (164) and likely contribute to the ability of 
viral factors to hijack the translational machinery.  
Another study employed an approach that was based on the comparison of 
cytoplasmic membrane fractions obtained from mock-infected and infected 
cells.  HnRNP K was identified as an interaction partner of alphavirus RCs. The 
hnRNP K protein also interacts with SINV sgRNA (165). Another cellular pro-
tein, HuR, has been shown to bind to the 3′ UTRs of genomic and sgRNAs, 
thereby protecting them against degradation. This interaction appears to be 
specific to the species of virus because it was observed for SINV (41), but not 
for CHIKV (166). Additionally, nsP3s of CHIKV, SINV and SFV have been 
shown to interact with host cell amphiphysins (proteins that are prominently 
involved in cellular membrane dynamics) and to recruit them to RCs (129).  
To document the interactions of alphaviruses with host cell components on a 
genome-wide scale, high-throughput Y2H screening was used to characterize 
the interactions between nsPs of CHIKV and human proteins (167). Inte-
restingly, only a few of the revealed proteins overlapped with the interaction 
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partners identified via pull-down experiments using tagged SINV nsP2 men-
tioned above (162). In addition, RC-bound nsP3 and nsP3 located in cyto-
plasmic granules has been shown to interact with different host proteins (135).  
An obvious approach for mapping virus-host interactions involves siRNA 
screens. These screens, which target many or all cellular proteins, have been 
performed for several alphaviruses, but complete data from any of these studies 
remain to be reported. Nevertheless these screens have been useful; they have 
led to the identification of NRAMP as the receptor for several alphaviruses 
(46), as well as to the discovery of the antiviral role of the nonsense-mediated 
mRNA decay pathway (168). Partners of the EU-funded ICRES (Integrated 
Chikungunya RESearch) consortium (our laboratory was part of this consor-
tium) performed a whole-genome siRNA screen to identify CHIKV host fac-
tors, resulting in the identification of 156 validated proviral and 41 validated 
antiviral host factors. Among these, six proviral factors could be targeted with 
approved chemical inhibitors, and the pharmacological targeting of these pro-
viral factors in mouse models of CHIKV also provided antiviral effects (Karlas 
et al., unpublished). 
Thus, multiple studies investigating alphavirus host factors have produced 
long lists of candidate proteins. However, knowledge concerning their precise 
roles and functions in the context of alphavirus infections is very limited. Addi-
tionally, the poor overlap between the results obtained using different methods 
suggests that only a fraction of the host proteins that are important for 
alphavirus infection have been identified. Therefore, many important host 
components remain to be identified, and almost all of these factors will require 
further analysis to characterize their precise roles, functions and mechanisms of 
actions in the context of alphavirus infection. 
 
 
2.7. Pathogenesis of SFV infections 
Virus-host interactions vary between different alphavirus species. Additionally, 
different strains of the same virus can have contrasting effects on the host. SFV 
is a prime example of this divergence, comprising strains that are designated as 
virulent or avirulent according to their pathogenicity in the central nervous 
system (CNS) of adult mice.  
 
2.7.1. Strains of SFV 
The various strains of SFV provide a well-characterized experimental system to 
study the pathogenesis of viral encephalitis. The most commonly used SFV 
strains include A7(74), SFV4, and L10. All of these strains infect neonatal and 
young suckling mice (up to 11 days old), causing lethal encephalitis (117). The 
ability to cause lethal infection in mice of this age group is not specific to SFV; 
rather, it is a property shared by many alphaviruses, including those, which do 
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not efficiently infect adult immunocompetent mice (169). However, the 
outcome of SFV infection in older mice ranges from asymptomatic for A7(74) 
to neurovirulent in the case of SFV4 and L10 (117).  
L10 originates from virus isolated from a pool of 130 Aedes africanus 
mosquitoes that were captured in the Semliki Forest, Uganda in 1942 (170). It 
was passaged eight times via intracerebral (i.c.) inoculation in the adult mouse 
brain, followed by two i.c. passages in the neonatal mouse brain (171). One 
aliquot that was sent from the Bradish laboratory (Porton Down, United 
Kingdom) to the Webb laboratory (London, United Kingdom) was further 
passaged twice in chicken embryo fibroblasts and stored at –80 °C. One of these 
aliquots was used in the present study (paper I) to obtain the consensus 
sequence of L10 by high-throughput sequencing.  
The prototype strain of SFV was isolated from the same pool of mosquitoes 
as L10; its passage history, however, is different. First, it was passaged four 
times by i.c. inoculation in the adult mouse brain (171). The subsequent passage 
history was not recorded, but it most definitely included several (based on some 
data, as many as sixteen) passages in BHK-21 cells. The prototype strain was 
the first SFV strain to be sequenced and used for the construction of a full-
length infectious cDNA (icDNA) clone. The cDNA clone was designated pSP6-
SFV4, and the obtained virus was designated SFV4 (12, 53, 172).  Of note, the 
same isolation (in 1942) gave rise to several other virulent SFV strains, 
including V13 (available from the ATCC as VR-67; http://www.lgcstandards-
atcc.org/ Products/All/VR-67.aspx) and E9. The Osterrieth strain of SFV, the 
only SFV strain that has caused a fatal case of infection in humans (173), 
originated from the laboratory of Prof. Paul M. Osterrieth, who himself 
obtained the SFV stock in 1957 from the Wistar Institute (USA). Given the 
timing, it is reasonable to assume that this virus must have originated from the 
1942 isolation and thus has a common source with SFV4 and L10. However, 
the passage history of the Osterrieth strain of SFV was different from the other 
strains’. It is unknown whether the original passage history of this stock is the 
same as that of the prototype strain; however, before the fatal accident, the virus 
had been passaged 13 times in primary chicken embryo fibroblasts, seven times 
i.c. in 4- to 5-week-old mice, and once subcutaneously in 6- to 7-week-old 
mice. The brain material of these mice was again passaged four times i.c. in 6- 
to 7-week-old mice and then once in BHK-21 cells. The patient worked with the 
supernatant collected from this passage (173). There is almost no information 
on what happened with the virus strain after the fatal accident or even whether 
or not this strain still exists. 
A7(74) was derived from the AR2066 strain by seven passages through 
neonatal mouse brain and two colony selections on chick embryo fibroblasts. 
The AR2066 strain was isolated from Aedes argenteopunctatus mosquitoes in 
Namancurra, Mozambique in 1959 (174). The aliquot used in the present study 
(paper II) to obtain the consensus sequence of A7(74) by high-throughput 
sequencing was received from H. E. Webb, who obtained it from the Bradish 
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laboratory, and was stored at –80˚C with minimal passaging. Another aliquot of 
A7(74) from the Webb laboratory was further passaged several times in MBA-
13 cells, subsequently plaque-purified three times on the same cells and used 
for sequencing, molecular analyses, and the construction of the icDNA clone of 
A7(74), which was designated rA774 (175).  
Thus, L10 and SFV4 originate from the same isolation of SFV virus, 
whereas the ancestor of A7(74) was isolated independently 15 years later from a 
different location and source. Both groups of viruses have a rather long in vivo 
passage history. In addition, the prototype strain and, accordingly, SFV4 have 
also undergone a long in vitro passage history. Of note, none of these strains has 
been passaged using mosquitoes/mosquito cells; however, the ability to infect 
vectors/vector cells has been maintained. Additional isolates of SFV have been 
collected after 1959 (although not recently), but these isolates have not provided 
any actively studied laboratory strains. Thus, the vast majority of modern 
studies of SFV virulence have been conducted using the A7(74), SFV4, and 
L10 strains of the virus.  
 
2.7.2. Neuroinvasion and CNS tropism 
The CNS is separated from circulating blood by the blood-brain barrier (BBB). 
Inoculation of the virus into the abdominal cavity (intraperitoneal (i.p.) 
inoculation) is the most commonly used route to study the ability of the virus to 
cross the BBB, i.e., neuroinvasiveness. Following i.p. inoculation, A7(74) and 
L10 first replicate in peripheral tissues and produce a high-titer plasma viremia 
that peaks at 24–48 h postinfection (176). This viremia is controlled by IFN 
response and then by antibodies (177). High-titer plasma viremia is thought to 
be a prerequisite of CNS infection; however, in nature, its main significance is 
to ensure the efficient transmission of the virus to insect vectors during a blood 
meal. Both A7(74) and L10 are rapidly neuroinvasive and enter the brain by 
traversing cerebral endothelial cells (178). In contrast, following low-dose i.p. 
inoculation, SFV4 produces lower plasma viremia and no virus can be detected 
in the brain (179).  
After entering the brain, A7(74) and L10 initially infect and replicate in 
perivascular oligodendrocytes and neurons but not in astrocytes (117, 177). L10 
spreads rapidly throughout the brain, producing fatal panencephalitis in mice of 
any age (176, 180, 181). Interestingly, following i.c. or intranasal inoculation, 
SFV4 is also neurovirulent, disseminates rapidly throughout the brain, and 
efficiently causes lethal encephalitis, as observed with the L10 virus. Thus, SFV4 
possesses a defect that reduces its peripheral infection and prevents efficient 
neuroinvasion. In contrast, the dynamics of A7(74) infection of the CNS varies 
according to the age of the mice. In neonatal mice, A7(74) disseminates rapidly 
in the brain and causes fatal infection. In the adult mouse CNS, the spread of 
A7(74) remains limited and concentrated to the perivascular foci that likely  
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Figure 6. Schematic representation of phenotypes of different SFV strains in an 
adult mouse model. IC indicates intracerebral inoculation; IP indicates intraperitoneal 
inoculation.  
 
represent the initial sites of viral entry into the CNS. The replication of A7(74) 
in mature neurons is severely restricted, and the virus is cleared from the brain 
by the immune response (176, 181). The avirulent strain does, however, induce 
a nonlethal demyelinating disease that generally lasts up to 30 days after 
infection (182). Interestingly, when administered i.c., A7(74) remains avirulent 
and replication in mature neurons is still restricted; however, widespread 
replication in oligodendrocytes in major white matter tracts can be observed 
(183). A schematic overview of SFV phenotypes is depicted in figure 6. 
 
2.7.3. Determinants of SFV virulence 
The molecular determinants responsible for the increased susceptibility of 
younger hosts to severe alphavirus-induced encephalitis are not completely 
known. This age-related virulence does not appear to depend on the maturity of 
specific immune responses. This conclusion is based on the results of studies 
using athymic nu/nu mice lacking T-lymphocytes and mice with severe 
combined immunodeficiency (SCID), which lack both T- and B-lymphocytes, 
and in which the replication of A7(74) remains restricted to small perivascular 
foci (176, 184). Rather, the age-related virulence of A7(74) is a function of 
CNS cell maturity. All three SFV strains replicate efficiently in immature 
neurons because these cells likely contain suitable membranes and biochemical 
pathways. During the first postnatal weeks, detailed connections in the neuronal 
network are finalized, and axogenesis, synaptogenesis, gliogenesis, and 
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myelination are being completed (181). Due to these changes, the ability of 
A7(74) to infect mature neurons becomes restricted: viral protein synthesis and 
RNA replication still occur, but the budding and consequent spread of the virus 
infection do not follow. Interestingly, when adult mice are pretreated with gold 
compounds, neurons become permissive to A7(74) replication, and the virus 
spreads rapidly throughout the brain, resulting in a panencephalitis that is 
similar to that caused by virulent L10 (185). Gold compounds are known to 
induce smooth membrane production in neurons, and one can assume that 
because alphaviruses require suitable membranes for replication and budding, 
the change in membrane synthesis and/or associated biochemical pathways may 
be the cause of age-related virulence of A7(74) (117). 
Prior to the present study, the viral determinants responsible for the different 
neurovirulence of SFV strains in adult mice have been shown to reside in the ns 
region. A chimera containing the structural genes from the molecular clone 
(rA774) of the avirulent A7(74) and the ns region of the SFV4 produces a 
highly virulent virus, while the reciprocal recombinant is asymptomatic. 
Furthermore, replacement of the nsP3 region of rA774 with that of SFV4 
reconstitutes the virulent phenotype, demonstrating that nsP3 of the virulent 
strain is sufficient to restore neurovirulence in an avirulent strain (175). It has 
been reported that deletions in the nsP3 hypervariable domain attenuate 
virulence after peripheral inoculation (186). However, the viruses used in this 
study were also severely attenuated in cell culture. Thus, it is more likely that 
compromised replication, and not some specific nsP3-related in vivo property, 
was the main contributor to the observed nonvirulent phenotype. Furthermore, it 
was also clear that the nsP3 gene might not be the only virulence factor and that 
other determinants must be present in the ns region (128). In contrast to the 
relatively well-studied differences between the virulence of A7(74) and SFV4, 
the molecular bases of the different phenotypes of SFV4 and L10 are not 
known. 
 
2.7.4. Immune response in the mouse CNS  
Viral infection triggers the production and secretion of a specific set of pro-
inflammatory cytokines, including type I IFNs (IFN-α/β), which play a central 
role in the host innate immune system and subsequent activation of adaptive 
immunity. In the case of alphavirus infection, the type I IFN system is impor-
tant for the initial control of infection, and both the humoral and cellular arms 
of the adaptive immune response participate in the elimination of the virus (8, 
187).  
The infection of immunocompetent cells with SFV is followed by a rapid 
response. Viral dsRNA is recognized by specific pathogen recognition receptors 
(e.g., toll-like receptors, cytoplasmic RNA helicases), which leads to the 
induction of type I IFNs (8). Furthermore, SFV replicase has also been shown to 
convert host cell RNAs into 5′-ppp dsRNA and induce IFN through the retinoic 
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acid-inducible gene I (RIG-I) pathway (188).  Both A7(74) and SFV4 activate 
type I IFN gene expression in the mature mouse brain, and this expression is 
proportional to the level of viral RNA (179, 189). A7(74) displays rapid 
virulence in IFNAR–/– animals lacking functional IFN-α/β receptors. The same 
is observed for SFV4: IFNAR–/– animals die from infection before the virus 
can reach the CNS. These data indicate that the type I IFN system strongly and 
successfully suppresses SFV by preventing widespread dissemination of the 
virus in extraneural tissues. Consistent with this, the lack of type I IFN response 
allows a more prominent A7(74) infection of ependymal cells lining the 
ventricles. In sharp contrast, the inability of A7(74) to infect and spread in adult 
brain neurons is not affected (179). Thus, the inability of A7(74) to infect 
neurons is not due to the type I IFN response. 
Both avirulent and virulent viral strains induce type I IFNs in in vitro cell 
culture (although to very different extents, see 5.3 and Fig. 7). In addition, they 
display different sensitivities to these cytokines. In IFN-treated cells, the 
avirulent strain shows no cytopathic effect and has a 100-fold lower viral yield 
than the virulent L10. The reduced susceptibility of the L10 strain to the action 
of IFN allows it to overcome the established IFN-induced antiviral state of the 
cell, increasing its virulence (190). The virulent strain’s tolerance to type I IFN 
is associated with the nsP3-nsP4 gene region of the virus and is distinct from 
the genetic loci responsible for SFV neurovirulence (191). 
The recovery of adult mice from infection by an avirulent virus requires 
immune-mediated viral clearance. The clearance is a nonlytic process and, 
based on results with experiments utilizing immunodeficient animal models, 
requires both functional T- and B-lymphocytes (117). In athymic nu/nu mice 
lacking T-lymphocytes, the blood titers of A7(74) are reduced to undetectable 
levels, but the brain titers remain high (192). In μMT mice, which lack 
functional B-cells and antibodies, the clearance of A7(74) is impaired, and the 
virus persists in both the serum and brain (177).  
In adult animals, A7(74) causes subclinical encephalitis that involves 
inflammatory demyelination of axons. Despite prolonged brain virus titers, no 
demyelinating lesions can be observed in infected nu/nu or SCID mice (184). 
Demyelination occurs in the brains of μMT mice, indicating that antibodies are 
not required for this process (177). The most likely mechanism underlying the 
generation of these lesions is CD8+ T-cell-mediated elimination of infected 
oligodendrocytes (176, 193) 
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3. AIMS OF THE STUDY 
Many of the studies investigating SFV neurovirulence have been conducted 
using reverse genetics, which became possible following the construction of 
molecular clones of virus strains such as rA774 and SFV4. These icDNA clones 
were developed long before the availability of next-generation sequencing. 
Therefore, it was originally not possible to verify whether the sequences of 
these clones corresponded to the consensus sequences of the respective strains. 
In addition, although the molecular clone derived SFV4 virus and natural L10 
virus are both virulent strains, they are not identical because low-dose i.p. 
inoculations result in consistent phenotypic differences. Thus, the findings 
obtained using the molecular clones and natural isolates are often difficult to 
interpret. Therefore, in the present study, we wanted to identify the consensus 
sequences of the natural A7(74) and L10 strains, generate new molecular clones 
corresponding to these sequences to confirm prior findings, and obtain new data 
regarding the determinants of SFV neurovirulence. The main objectives of this 
study were as follows: 
1. Construct a consensus clone of the L10 strain and assess the molecular 
determinants and mechanism(s) responsible for the phenotypic differences 
between SFV4 and L10. 
2. Use the consensus clones of A7(74) and L10 to confirm the role of nsP3 in 
neurovirulence and reveal the molecular bases for the phenotypic difference. 
3. Characterize other potential determinants important for SFV neurovirulence 
and reveal their molecular basis. 
4. Use a new approach to analyze the proteins associated with SFV replication 
organelles to expand knowledge regarding alphavirus-host interactions.  
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4. MATERIALS AND METHODS 
Methods of basic molecular biology, virology and cell biology used in the present 
study are described in detail in materials and methods sections of publications I, 
II, III that are included into this dissertation. Original methodology developed 
for magnetic separation of alphavirus replication organelles is briefly described 
in section 5.4 and is provided in detail in paper III. Therefore, descriptions of 
these methods are not repeated here. 
 
Methods used for sections of results that are not described in attached publi-
cations include: 
 
a. Analysis of IFN-β production in virus-infected cell cultures 
Mouse fibroblast COP5 cells (194) were maintained in L-glutamine containing 
Iscove's Modified Dulbecco’s Medium (IMDM, Gibco) supplemented with 10% 
fetal bovine serum (FBS). Stocks of SFV6, SFV6-74, SFV6-RE, SFV6-74-RE, 
A774wt, A774wt-6, A774wt-HV and A774wt-6-HV were obtained and con-
centrated by ultracentrifugation as described in papers I and II. COP5 cells 
were infected at a multiplicity of infection (MOI) of 0.1 with wt or recombinant 
viruses. At 24 h postinfection the supernatants were collected; the VeriKine-
HSTM Mouse IFN Beta Serum ELISA Kit (PBL Assay Science) was used to 
measure levels of IFN-β according to manufacturer’s instructions.   
 
b. Construction and use of SFV trans-replicase system 
Construction of plasmids for expression of SFV replicase was performed as 
follows. 
First, part of the SFV6 cDNA sequence, consisting of fragments spanning 
from residue 85 to residue 280 (including Eco RV restriction site at position 
277) and from residue 6712 to 7422 (including Bgl II restriction site at position 
6715) flanked with Bsp 119I (at 5’ end) and Spe I (at 3’ end) restriction sites 
was ordered as synthetic DNA (GenScript, USA). The initiation codon for the 
reading frame of ns proteins was placed in a strong Kozak context. This 
sequence was cloned into a pUC57Kan vector plasmid. The remaining part of 
the ns polyprotein encoding region was transferred to this plasmid from 
plasmids encoding for the full length sequences of SFV6, SFV6-74, SFV6-RE, 
SFV6-74-RE, A774wt, A774wt-6, A774wt-HV and A774wt-6-HV using Eco 
RV and Bgl II restriction sites. In clones encoding for the replicase of A774wt, 
A774wt-6, A774wt-HV and A774wt-6-HV the Arg2429 residue (numbered 
according the P1234 of SFV) was replaced with a Lys residue (the natural 
amino acid residue of A774wt at this position). The inserts corresponding to the 
regions encoding for ns polyproteins were placed between the immediate-early 
promoter of human cytomegalovirus (CMV) and the simian virus 40 (SV40) 
late polyadenylation signal in the pMC-gtGTU2 expression vector plasmid (FIT 
Biotech Plc, Finland) using Bsp 119I and Spe I restriction sites. Sequences of all 
obtained expression constructs were verified using Sanger sequencing. 
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The expression cassette encoding the truncated SFV mini-genome RNA 
comprised the following elements: the CMV promoter, the 5’ UTR of SFV6 
together with first 74 codons of the nsP1 encoding region, the second intron 
from the human beta globin gene, the sg promoter of SFV (from position –70 to 
+51 with respect to the sgRNA transcription start site), the coding sequence of 
Gaussia luciferase (Gluc) reporter, the 3’ UTR of SFV6 followed by 69 adenine 
residues, the hepatitis delta virus negative strand ribozyme, and the SV40 late 
polyadenylation signal. The cassette was obtained as synthetic DNA (GenScript, 
USA) and cloned into a pBluescript KS vector.  
Transfection and IFN-β measurements were performed as described in (188). 
Briefly, COP5 cells were transfected with constructed plasmids encoding either 
wt or recombinant SFV replicase using Lipofectamine 2000 (Invitrogen). At 24 
h posttransfection the supernatants were gathered and the amount of IFN-β 
secreted into the cell culture medium was measured using a commercial 
VeriKine-HSTM Mouse IFN Beta Serum ELISA Kit (PBL Assay Science) 
according to the manufacturer's instructions. The ability of wt and recombinant 
replicases to replicate SFV mini-genome was analyzed by measurement of Gluc 
activity in COP5 cells co-transfected with plasmids encoding for SFV replicase 
and mini-genome. 
10
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5. RESULTS AND DISCUSSION 
5.1. The ability of SFV to enter the CNS is 
determined by charged amino acid residues  
on the surface of E2 glycoprotein (I) 
Alphaviruses, similarly to other RNA viruses, have error-prone polymerases 
and thus exist as a mixed population of genotypes called quasispecies. Although 
SFV4 and L10 originate from the same pool of mosquitoes, they have a dif-
ferent passage history and display different phenotypes in mouse model. Fol-
lowing i.c. infection or i.p. inoculation with a very high dose (≥106 plaque 
forming units, PFUs) of virus, the pathogenesis of SFV4 and L10 is similar: 
both viruses are virulent, and the infected mice die from encephalitis. However, 
following low dose i.p. inoculation – a more biologically relevant condition, as 
mosquitoes cannot deliver a high dose or i.c. infection – L10 still produced 
high-titer plasma viremia and was rapidly and efficiently neuroinvasive, 
generating fatal panencephalitis, whereas SFV4 produced low-titer viremia, was 
rarely neuroinvasive, and displayed low virulence (I, Fig. 1 and Fig. 2). All the 
animal experiments in publications I and II, unless stated otherwise, were per-
formed using low dose (5000 PFUs) i.p. inoculation.  
 
5.1.1. The phenotypic differences between SFV4 and  
L10 map to E2 position 162 
To determine the genetic differences that are responsible for the different phe-
notypes, we sequenced an archived stock of L10 strain of known provenance 
using high-throughput sequencing. The obtained consensus sequence was com-
pared with the published sequence of SFV4 (GenBank accession number 
KP699763), and twelve nucleotide differences throughout the genome were 
identified (I, Table 1). Six of these changes, one in nsP3, two in the capsid 
protein, and three in the E2 protein coding sequence, were nonsynonymous. 
Although nucleotide changes that do not affect the amino acid sequence of 
virus-encoded proteins could also be responsible for the phenotypic differences, 
it is more likely that one or more of the six nonsynonymous differences were 
responsible for the variance in neuroinvasion. Therefore, these six changes were 
engineered into the SFV4 icDNA clone to generate a new molecular clone; the 
virus produced from this clone was designated SFV6 (GenBank accession 
number KT009012). The amino acid sequences of the proteins encoded by 
SFV6 are identical to the consensus amino acid sequences of the proteins 
encoded by L10. In BHK-21 cells, the new SFV6 virus as well as other 
recombinant viruses described below grew to titers similar to those of SFV4, 
with no significant differences in growth kinetics. However, compared to SFV4, 
SFV6 produced larger plaques on monolayers of BHK-21 cells. This difference 
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in the in vitro phenotype became an indirect indicator of the neuroinvasive 
ability of recombinant viruses. Following a low dose i.p. inoculation into 
BALB/c mice, SFV6 produced high-titer viremia, was efficiently neuroinvasive 
and all of the infected mice rapidly reached clinically defined endpoints (I, Fig. 
1). Therefore, it was concluded that we had generated an icDNA molecular 
clone, which, for the first time, produced SFV virus with the same phenotype as 
L10 and the prototype biological strains. 
To further investigate the effect of these six nonsynonymous differences on 
the phenotype of the virus, the corresponding substitutions were introduced, 
individually or in combination, into the SFV4 or SFV6 molecular clones, and 
recombinant viruses were generated and analyzed. SFV4-nsP3 (SFV4 
containing the E1384A substitution in the nsP3 region) remained avirulent. In 
contrast, SFV4-struct (SFV4, in which the structural region was replaced with 
that of SFV6) produced high titers in the blood, was detected in the brain, and 
was virulent (I, Fig. 1). Therefore, it was concluded that one or more of the 
amino acid substitutions in the structural polyprotein had to be responsible for 
the differences in neuroinvasion.   
Replacement of the capsid protein of SFV6 with that of SFV4 (SFV6-C) did 
not change the neuroinvasive phenotype: the virus remained virulent. However, 
when the E2 envelope protein of SFV6 was replaced with that of SFV4 (SFV6-
E2), the virus became phenotypically similar to SFV4, revealing that the genetic 
locus responsible for the differences in viremia, neuroinvasion, and virulence 
mapped to E2 (I, Fig. 1). The ability of a single-amino-acid change in E2 to 
affect neurovirulence in mice has been observed previously for SINV, VEEV, 
and EEEV (195-198). Indeed, subsequent analyses revealed that all re-
combinant viruses carrying a lysine residue at position of 162 of E2 (162K) had 
small plaques (similar to SFV4, which also has 162K) on BHK-21 cells; in 
contrast, viruses with glutamic acid residue in the same position (162E) 
produced large plaques similar to SFV6. Like SFV4, the small plaque virus 
SFV6-162K generated low-titer viremia and was not detected in the brain. The 
large plaque SFV4-162E, like SFV6, generated high-titer viremia and was 
detected in the brain (I, Fig. 1). Based on these data, it was concluded that 
E2 162E is a determinant of SFV6 (and correspondingly, L10) neurovirulence. 
Interestingly, position 162 of E2 has been described previously as a molecular 
determinant of SFV virulence (199). However, in that study, infection of 
pregnant BALB/c mice with high-dose SFV4 was attenuated if E2 162 was 
changed from lysine to glutamic acid. The brain titers of these viruses were not 
reported, making it difficult to compare the data to our present findings. It may 
be hypothesized that the charge at E2 162 affects the ability of the virus to cross 
the placenta and/or that a virus with enhanced binding to heparin sulfate (see 
5.1.3) had some growth advantage in pregnant mice. 
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5.1.2. The biological stock of L10 is heterogeneous  
at position 247 of E2 
Although the amino acid sequence of SFV6-encoded proteins matched the 
consensus amino acid sequence of L10 proteins, the inoculation of these two 
viruses into mice revealed a small but consistent difference in phenotype. 
Viremia for SFV6 was higher than for L10 on postinoculation day (PID) 1 (I, 
Fig. 1B) and, in general, SFV6-infected mice also reached the clinical endpoint 
of the experiment earlier than L10-infected mice. The L10 stock used in this 
study originated from the virus that was isolated in 1942 (170) and underwent 
various recorded passages, including in vitro passages in chicken embryo 
fibroblasts, after which it was stored frozen for 32 years. The stock was then 
passaged once on BHK-21 cells to generate new stocks of the virus, which were 
used to study the acute encephalitis induced by L10 virus (200). To our 
knowledge, this L10 strain stock had never been plaque-purified and therefore 
was assumed to contain viruses with different properties. Indeed, the L10 stock 
produced distinct (small, medium and large) plaques on BHK-21 cells (I, Fig. 
3A), which indicated that the L10 stock contained at least three different 
genotypes. In mice, the small-plaque virus produced low viremia, was 
undetectable in the brain, and was avirulent, whereas the large-plaque virus 
replicated well in the periphery, entered the brain, and was virulent (I, Fig. 3C – 
3F). In the small-plaque viruses, one nucleotide difference (compared to the 
L10 consensus sequence), at position 9160 led to the replacement of a 
negatively charged glutamic acid (L10 consensus) to a positively charged lysine 
residue at position 247 of the E2 protein (E247K). This E2 variation was also 
found by analysis of the high-throughput sequencing data of the L10 stock (I, 
Fig, 3B), demonstrating the relative abundance of the corresponding genomes. 
As the corresponding recombinant virus (SFV6-247K) was avirulent (I, Fig 4), 
it was concluded that the charge of amino acid residue 247 of E2 is another 
determinant of SFV viremia and neuroinvasion. The presence of quasispecies 
with various extents of virulence in the L10 stock highlights the importance of 
molecular clones in research and, therefore, the usefulness of SFV6. Further-
more, it demonstrates the importance of minimal in vitro passaging of wt 
viruses before engineering a molecular clone. 
The L10 large-plaque variant and SFV6 carried a negatively charged 
glutamic acid at positions 162 and 247 of E2 and were both virulent. Small 
plaque viruses had a positively charged lysine residue in at least one of these 
positions (small-plaque variant of the historic L10 stock at position 247 and 
SFV4 at position 162), produced low-titer viremia and displayed low virulence. 
Finally, both E162K and E247K mutations in the E2 protein converted SFV6 
into a small-plaque, low-level viremia, nonneurovirulent virus (I, Fig. 4), 
confirming that each of these E2 charge reversions was sufficient to cause this 
phenotypic change. These mutations, which are apparently unfavorable for in 
vivo infection, most likely originate from the passaging of virus stocks in cell 
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culture and/or i.c. passaging in mouse brain (see 5.1.4). Indeed, serial passaging 
of four biological replicates of SFV6 on BHK-21 cells confirmed that this 
process selects for positively charged amino acid residues in E2 (I, Table 2). 
Similar changes, resulting in the appearance of positively charged amino acid 
residues in the E2 proteins, introduced by site-directed mutagenesis or selected 
for by passaging, have also been shown to cause a reduction of peripheral virus 
titers, rapid clearance from the blood, and low virulence in other alphaviruses 
(195, 201, 202).  
 
5.1.3. Charged amino acid residues at positions 162 and  
247 of E2 modulate the binding of SFV virions  
to heparan sulfate 
Based on the analyses of the 3D structure of the alphavirus E1/E2 heterodimer, 
the amino acid residues 162 and 247 were predicted to lie within the acid-
sensitive region of E2. The residues are located on the surface of the 
heterodimer; similarly, they clearly lie on the surface of the 3D structure of the 
spike (I, Fig. 7). Therefore, positions 162 and 247 of E2 are readily available to 
bind proteins and other molecules such as cell surface receptors. In SINV the 
selection for positively charged amino acid residues in E2 promotes binding to 
the glycosaminoglycan (GAG) heparan sulfate (HS) (201). Furthermore, 
mutations analogous to those described herein have been shown to affect the 
binding of virions to HS in other alphaviruses, including RRV, CHIKV, EEEV 
and VEEV (195, 203-205).  
GAGs such as HS are ubiquitously expressed, negatively charged poly-
saccharides that are found on the surface or in the extracellular matrix of both 
vertebrate and invertebrate cells (206-208). In general, proteins bind to 
negatively charged HS via positively charged lysine and arginine residues. 
Studies have shown that when HS-binding proteins are injected intravenously, 
they are rapidly cleared from the circulation through binding to tissue HS (209, 
210). This clearance can be interrupted by the injection of heparinase, which 
digests HS on the tissue surface, or by coinjecting with heparin (209, 211). 
Thus, virions of alphaviruses that efficiently bind to HS are most likely cleared 
from the periphery via the same mechanism, resulting in reduced viremia. This 
phenomenon may be due to absorption of the HS-binding virus in the liver, an 
organ rich in GAGs (195).  
The present study confirmed that different strains of SFV and recombinant 
viruses vary in their interactions with HS. Positively charged lysine residues 
either at position 162 or 247 in E2 of SFV augment entry of the virus into CHO-
K1 or BHK-21 cells through increased binding to GAGs such as HS (I, Fig. 8A, 
8B). Furthermore, in a competition assay, preincubation with heparin efficiently 
reduced the number of plaques of SFV variants harboring E2-162K or E2-247K 
residues. The SFV variants carrying a glutamic acid residue at either of these 
positions were less affected (I, Fig. 8C). This data is consistent with recent 
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findings demonstrating that the interactions of CHIKV E2 with GAGs diminish 
dissemination of the virus to lymphoid tissues and stimulation of inflammatory 
responses (212). Increased binding to HS has also been associated with a 
decrease in the neurovirulence of VEEV and the flavivirus Murray Valley en-
cephalitis virus (195, 213).  
The data illustrates ability of SFV (and that of RNA viruses in general) to 
adapt quickly to different conditions (including cell culture conditions) during 
serial passaging. The SFV strains were isolated a long time ago and went through 
extensive in vitro and in vivo passaging before methods allowing construction 
of stable molecular clones were developed. Changes previously acquired by 
viruses, such as changes in viral envelope proteins favorable for i.c. (see 5.1.4) 
and cell culture propagation, were fixed in the sequences of obtained molecular 
clones. As we saw with SFV and as shown for other alphaviruses, these dif-
ferences can lead to major changes in the in vivo properties of the virus. There-
fore, the data obtained with viral strains passaged multiple times in cell culture 
or with molecular clones obtained from these strains should be interpreted with 
caution, as properties of such viruses do not necessarily correlate with those of 
original biological stocks. Now that next generation sequencing is readily avail-
able, new virus isolates should first be sequenced, and molecular clones corre-
sponding to the consensus sequence can then be obtained as synthetic DNA and 
used in subsequent experiments. However, for many model viruses, the original 
biological samples no longer exist. In the case of stocks with long passage 
history it is difficult, if not impossible, to be sure that their current phenotypes 
correspond to those at the time of their isolation.  
 
5.1.4. Amino acid residues 162 and 247 in E2 affect  
SFV replication in the mouse brain following i.c.  
inoculation and the effect of virus infection on  
the integrity of a BBB model 
To determine whether amino acid residues 162 and 247 of E2 affect SFV 
replication in the brain, parental and recombinant viruses were i.c. inoculated 
into mice, and brain titers were determined. As expected, all of the viruses 
replicated in the brain; however, SFV4, SFV6-162K, and SFV6-247K had 
higher titers than SFV6 and SFV4-162E (I, Fig. 5). This result is consistent with 
previous reports showing that wt SFV4 inoculated intranasally (a direct neural 
route to the CNS) is more virulent than SFV4 mutant harboring residue 162E in 
E2 (214). Similarly, greater binding to HS is associated with increased neuro-
virulence in neonatal mice infected with SINV, in adult mice inoculated i.c. 
with SINV, and in adult mice inoculated i.c. with a natural North American 
strain of EEEV (197, 198, 215). Thus, lysine residues at positions 162 and 247 
of E2 of SFV attenuate peripheral SFV replication but, at the same time, enhance 
its replication in the CNS. Therefore, it is possible that presence of virus 
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variants carrying the E2 247K residue in the L10 stock may originate from 
repeated i.c. passaging (rather than from in vitro passaging) of this SFV strain. 
To investigate whether neuroinvasion was related solely to the level of 
viremia or also to the ability of the virus to cross the BBB, the ability of dif-
ferent viruses to traverse an in vitro model of the BBB (Corning Transwell co-
culture system) was assessed. SFV6 or SFV6-162K was added to the luminal 
side of the BBB, and the integrity of the BBB was measured. In this 
experiment, avirulent SFV6-162K had a greater effect on the integrity of the 
BBB (I, Fig. 6A); additionally, a greater amount of virus was detected on the 
abluminal side of the BBB following infection with SFV6-162K compared to 
SFV6 infection (I, Fig. 6B). However, it is not clear how well these findings 
reflect the in vivo infection because cells in culture have more GAGs on their 
surface; thus, the increased ability of SFV6-162K to cross the artificial BBB 
may simply reflect this feature. Similarly, it has been reported that the ability of 
strains of HIV to cross an in vitro BBB correlates with their HS binding 
efficiency (216, 217). Taken together, these results suggest that the ability of 
SFV to cross the in vitro BBB correlates with its enhanced replication ability in 
the brain but not with the ability to generate high-titer viremia.  
 
 
5.2. The neurovirulence of SFV is affected by 
differences in determinants of ns polyprotein 
processing and by the sequence of nsP3 (II) 
In adult mice, infection with neurovirulent SFV strains leads to lethal 
encephalitis, whereas mice infected with the avirulent A7(74) strain remain 
asymptomatic. Previously, a molecular clone of A7(74) designated as rA774 
was constructed, and the rescued virus was compared to SFV4. The deter-
minants of virulence were mapped to the ns region of these viruses. Moreover, 
the importance of nsP3 for SFV virulence was established (175). However, as 
shown in publication I, SFV4 is not truly virulent because its ability to replicate 
in the periphery is attenuated. In addition, we observed that in vitro transcripts 
of rA774 display an abnormally low quality and infectivity, suggesting that this 
molecular clone may also carry uncharacterized functional defect(s).  
 
5.2.1. A single amino acid difference from the A7(74) 
consensus sequence causes low infectivity of rA774 
The consensus sequence of a biological stock of A7(74) of known provenance 
was determined using high-throughput sequencing and compared with rA774 
(175). This revealed a single nonsynonymous difference in codon 1347 
(corresponding to amino acid residue 11 in nsP3) of the ORF of the ns 
polyproteins: in the consensus sequence of A7(74) it encodes Ile, in rA774 it 
encodes Val. The correct molecular clone of A7(74) was obtained by changing 
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the Val1347 codon in rA774 to the Ile codon. This clone, which was designated 
A774wt, had efficiency of infectious virus rescue over 100-fold higher than 
rA774, confirming that the presence of the incorrect amino acid at position 
1347 was the cause of the low infectivity of the rA774 clone (II, Fig. 1B). 
Interestingly, this substitution was previously mistakenly thought to represent a 
natural sequence difference between SFV4 and A7(74), and the correct A7(74) 
molecular clone (designated rA774-V11I) was actually constructed and to some 
degree even analyzed (128). Thus, the properties of viruses rescued from 
icDNA clones of SFV4 and rA774 differ from those of their respective SFV 
biological isolates, and the results obtained with them are difficult to interpret. 
Hence, it was important to verify and further characterize the determinants of 
virulence residing in the ns region of SFV using new consensus clones. 
Combined data from three experiments revealed that A774wt killed 5 of 51 
mice and was therefore, in contrast to the original avirulent A7(74) (176, 218), 
slightly virulent. However, this finding is consistent with previously published 
data for rA774-V11I (128). Our earlier in vivo experiments demonstrated that 
SFV6 is also slightly more virulent than the parental L10 strain, which indicates 
that slightly enhanced virulence may be a common property of consensus 
clones of SFV (and possibly other alphaviruses). SFV6 and A774wt correspond 
to the most common (and possibly the fittest) sequences of the L10 and A7(74) 
strains, and unlike the native isolates, P0 stocks (viruses rescued directly from 
infectious clones) display little sequence variation and may therefore have a 
higher virulence.  
 
5.2.2. The introduction of synonymous changes  
reduces recombination between two copies  
of nsP3-encoding sequences 
The analysis of chimeras between SFV4 and rA774 demonstrated that nsP3 is 
the main virulence determinant of SFV4 (175). Thus, either nsP3 of SFV4 is the 
factor that causes virulence, or nsP3 of rA774 serves as the factor that restricts 
SFV virulence. However, it remains unclear which phenotype caused by nsP3 – 
the virulent or the avirulent phenotype – is dominant. To directly address this 
question, recombinant viruses carrying two nsP3-encoding regions were 
constructed and analyzed. In these viruses, the region encoding nsP3 of SFV6, 
which lacks the opal terminator, was used as upstream copy of nsP3. This order 
of nsP3 regions ensured that the recombinant viruses would express both nsP3 
proteins at equivalent levels. 
It should be mentioned that although viruses containing extra sequences rep-
resent useful research tools, the duplication of RNA virus genes represents a 
significant challenge. This is because duplication of nsP3 increases the size of 
the SFV genome by approximately 12.5%, which slows down its replication. It 
also creates an unnatural processing site between the two nsP3 regions in the 
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P12334 polyprotein. A previous study demonstrated that this type of manipula-
tion is tolerated (219) but may still affect the biological properties of the virus.  
The first attempt to construct such tools failed: we were unable to obtain 
homogeneous stocks of viruses containing two identical or highly similar nsP3-
encoding regions (the corresponding sequences of A774wt and SFV6 have an 
identity of 96%). Genetic analysis confirmed that copy-choice recombination 
between these identical (or nearly identical) nsP3 sequences was highly 
efficient and generated viruses with a single copy of nsP3. To increase the 
stability of the recombinant genome, the similarity between two copies of nsP3-
encoding regions was reduced to a nonsignificant level by the introduction of 
numerous synonymous changes into the upstream copy of nsP3 encoding 
region. The resulting panel of viruses comprised A774wt, SFV6, and double 
nsP3 viruses designated as A774wt-6/74, A774wt-6/6, SFV6-6/74, and SFV6-
6/6. All of the recombinant constructs exhibited an infectious virus rescue 
efficiency that was similar to the parental clones (II, Fig. 1B). However, viruses 
carrying two copies of nsP3 exhibited a delay in accumulation of infectious 
progeny and reached titers that were approximately one log lower than the 
parental virus titers (II, Fig. 1C, 1D), likely due to the larger sizes of their 
genomes. 
Genetic analysis of P0 stocks of recombinant viruses confirmed the presence 
and stability of viruses harboring two copies of nsP3 (II, Fig. 3A). Western blot 
analysis revealed that these viruses expressed somewhat more nsP3 than 
A774wt and SFV6 (II, Fig. 3B). At the same time, an extra copy of nsP3 did 
not appear to interfere with the localization of virus replication organelles or 
individual ns proteins (II, Fig. 2A, 2B). Additionally, the presence of an extra 
copy of nsP3 did not cause major defects in the ns polyprotein processing 
patterns, as indicated by the results of pulse-chase experiments. The expression 
of two nsP3 proteins with slightly different mobilities was clearly detected for 
SFV6-6/74. In SFV6-6/6-infected cells, a band corresponding to the P33 poly-
protein was observed (II, Fig. 3C). An unexpected finding was the stabilization 
of nsP4. In sharp contrast to SFV6-infected cells, the amount of free nsP4 in 
SFV6-6/74- and SFV6-6/6-infected cells increased during the chase period, 
clearly indicating that nsP4 in these viruses was protected against degradation 
(II, Fig. 3C).  
 
5.2.3. Neurovirulence is the dominant function of nsP3 of SFV6 
Following a detailed in vitro analysis, the panel of viruses was used in in vivo 
experiments to determine which phenotype associated with nsP3 – virulent 
(SFV6) or avirulent (A774wt) – was dominant. The animal experiments 
revealed that all of the mice inoculated with SFV6 reached a clinical endpoint; 
in contrast, only 3 of 37 mice infected with A774wt developed disease. Both 
A774wt-6/74, which killed 15 mice, and A774wt-6/6, which killed 19 of 37 
mice (II, Fig. 4A), were significantly more virulent than the parental A774wt 
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but less virulent than SFV6. SFV6-6/74 and SFV6-6/6 were virulent and killed 
five and four out of seven mice, respectively (II, Fig. 4B). 
Both A774wt and SFV6 produced high-level viremia and were detected in 
the brain (II, Fig. 4E). The brain titers of SFV6 were significantly higher than 
those of A774wt, confirming that only the virulent strain, SFV6, replicated 
efficiently and spread rapidly throughout the brain. Due to their slower repli-
cation, the viruses harboring two copies of nsP3 produced significantly lower 
blood titers on PID 1 (approximately 104 PFU/ml on average) compared with 
A774wt and SFV6 (II, Fig. 4C). By PID 3, this difference was less prominent 
(II, Fig. 4D). Interestingly, on PID 3, double nsP3 viruses were detected in the 
brains of 7 of 20 mice, indicating that low viremia did not prevent entry into the 
brain (II, Fig. 4E). By the time animals had reached the terminal endpoint of the 
experiment and were euthanized (PID 7–10), the brain titers of these viruses 
were similar to the titers of virulent SFV6. In addition, RT-PCR analysis 
revealed that the viruses that had replicated in the brain maintained the extra 
copy of nsP3 (II, Fig. 4F). Therefore, double nsP3 viruses were not only able to 
reach the brain but also replicated and accumulated in brain tissues. 
The ability of viruses that were unable to induce high-titer viremia to enter 
the brain is inconsistent with the findings reported in publication I, in which an 
inability to cause high-titer viremia clearly hampered the virulence of SFV4. 
SFV4 infection resulted in viremia with a titer >104 PFU/ml at PID 1 and ≈102 
PFU/ml at PID 3, which was insufficient for the entry to the brain (I, Fig. 1). 
Infection with A774wt-6/6, which was apparently the most stable among the 
viruses with two copies of nsP3 (II, Fig. 4F), resulted in even lower blood titers 
(≈102 PFU/ml both at PID 1 and PID 3, II, Fig. 4C, 4D). However, in contrast 
to SFV4, A774wt-6/6 entered and replicated in the brain to high titers, 
ultimately killing 19 of 37 mice (II, Fig. 4A). Thus, a low blood titer per se 
does not prevent entry of SFV to the mouse brain. Several explanations may be 
provided for this apparent contradiction. In the case of SFV4, the low viremia 
results from enhanced clearance of the virus from the blood, most likely due to 
the binding of virions to HS. As a result, the decline in the virus titer (from PID 
1 to PID 3) is rapid and irreversible. In contrast, low titers of A774wt-6/6 and 
other viruses carrying two copies of the nsP3 gene are caused by their slower 
replication (II, Fig. 1C, 1D), and the decline in blood titers from PID 1 to PID 3 
is small or even undetectable (II, Fig 4C, 4D). Thus, viremia caused by these 
viruses persists for a longer duration, providing more opportunities to enter the 
brain. In addition (or alternatively), the different abilities to bind HS result in 
the attachment of virions to different receptors and cell types, which may affect 
the entry of SFV into the mouse brain. Finally, short-term but efficient 
replication of SFV4 and longer but slower replication of A774wt-6/6 (and 
similar viruses) may cause different antiviral innate immune responses, which 
may also affect the outcome of infection. 
The similar virulence of SFV6-6/74 and SFV6-6/6 indicated that nsP3 of 
A774wt was unable to efficiently reduce the virulence of SFV6. Consistently, 
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both A774wt-6/74 and A774wt-6/6 killed approximately 50% of the infected 
mice (II, Fig. 4A). This result clearly demonstrated that the insertion of nsP3 of 
SFV6 into the A774wt genome increased the virulence of the recombinant 
viruses regardless of the presence (A774wt-6/74) or absence (A774wt-6/6) of 
nsP3 from the avirulent strain (II, Fig. 4A). Thus, the neurovirulent phenotype 
caused by the presence of nsP3 of SFV6 was dominant. Alternatively, it is 
possible that the phenotype associated with the first copy of nsP3 (which was 
always nsP3 from the virulent SFV6 in the present study) was dominant. To test 
this hypothesis, viruses carrying the reverse order of the nsP3 copies (nsP3 from 
A774wt followed by nsP3 from SFV6) should be analyzed. The challenge 
associated with such an experiment is that the opal stop codon at the end of the 
nsP3-encoding region of A774wt would drastically reduce the expression level 
of the second copy of nsP3. This phenomenon would make it virtually 
impossible to compare the data obtained using such recombinant viruses with 
that presented above, and thus the experiment was not performed. 
Consistent with previously published results (175), we found that A774wt-6 
was virulent (II, Fig. 5B). The virus produced high-titer viremia and had 
significantly higher titers in the brain at PID 3 than did A774wt (II, Fig. 5). 
Surprisingly, however, SFV6-74 was as virulent as parental SFV6 and killed all 
of the infected mice with essentially the same kinetics (II, Fig. 5B). These data 
confirmed the presence of other virulence determinant(s) in the ns region of 
SFV6 (outside of nsP3) and revealed that nsP3 of A774wt could not eliminate 
the virulent properties of these determinants. 
 
5.2.4. Differences in the P4 position of the 1/2 cleavage site  
of P1234 and the S4 subsite of nsP2 protease affect the 
processing of ns polyprotein and virulence 
The sequences of the nsP4 proteins of A7(74) and L10 are nearly identical, and 
therefore the determinant(s) responsible for the contrasting virulence of A774wt 
and SFV6-74 most likely reside(s) in the nsP1 and/or nsP2 region(s) (II, Table 
1). In a parallel study, we observed that SFV4 showed poor tolerance to a His to 
Arg substitution in the P4 position of the 1/2 cleavage site of P1234. This mutant 
survived only through the generation of compensatory changes that sometimes 
occurred at amino acid residue 515 of nsP2 (Lulla et al., unpublished). Another 
study also predicted the functional linkage between position P4 of the 1/2 site and 
amino acid residue 515 of nsP2, which was shown to be part of the protease S4 
subsite (220). Therefore, we were interested in determining whether these 
amino acid residues, which are His and Val in L10/SFV6 but Arg and Glu in 
A7(74)/A774wt, are important for SFV virulence. Two new viruses, designated 
A774wt-HV and SFV6-74-RE, were constructed and analyzed (II, Fig. 6A). 
A774wt-HV had a virulent phenotype and killed 6 of 7 mice (II, Fig. 6B). In 
contrast, SFV6-74-RE was clearly less pathogenic than SFV6-74 and killed 
only 2 of 7 mice (II, compare Fig. 6B and Fig. 5B). These data demonstrated 
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that differences in the P4 position of the 1/2 cleavage site and the S4 subsite of 
the nsP2 protease affect the virulence of SFV.  
In the virulent strain of SINV, a mutation in nsP1, which is located close to 
the 1/2 site of the ns polyprotein, results in the acceleration of P123 processing 
and significant attenuation of neurovirulence (221). To determine whether 
substitutions altering the virulence of SFV also affect ns polyprotein processing, 
pulse-chase experiments with A774wt, A774wt-HV, SFV6-74 and SFV6-74-
RE were performed. This experiment revealed that the speed of P123 pro-
cessing clearly differed between avirulent and virulent viruses: cleavage of the 
1/2 site was faster in A774wt and SFV6-74-RE and slower in A774wt-HV and 
SFV6-74 (II, Fig. 7A, 7B). Interestingly, the reverse was observed for pro-
cessing of the 3/4 site: the P34 polyprotein was efficiently cleaved in viruses 
with Val515 in nsP2 (A774wt-HV and SFV6-74) but was not so readily cleaved 
in A774wt and SFV6-74-RE (II, Fig. 7A). Most likely the reduction of basal 
protease activity of nsP2, caused by the Val515 to Glu substitution, 
compensated for the presence of the Arg residue (the most favorable residue for 
fast processing) in the P4 position of the 1/2 site.  
These data and the results obtained with SINV (221) demonstrate a 
correlation between the speed of ns polyprotein processing and neurovirulence. 
However, the mechanism by which the accelerated cleavage of the 1/2 site 
and/or reduced protease activity of nsP2 affect the in vivo phenotype of the 
virus is less obvious. One possibility is that faster processing of the 1/2 site 
allows less time for the proper formation of RCs and may reduce the amount of 
functional RCs in some types of infected cells (possibly in mature neurons). 
Alternatively (or in addition), it is possible that the reduced protease activity of 
nsP2 or altered kinetics of P123 processing affect other virus/cell interactions, 
such as the induction of type I IFN production or interference with IFN 
signaling. In SINV, accelerated processing of the 1/2 site diminishes the ability 
of the virus to reduce STAT1/STAT2 phosphorylation (151). Our unpublished 
results clearly demonstrate that mutations that affect SFV neurovirulence also 
affect the ability of the virus to induce type I IFN response (see 5.3). 
 
5.2.5. The role of nsP3 in SFV neurovirulence and replication 
The mechanism(s) by which nsP3 affects the virulence of SFV remains even 
more obscure. The most obvious difference between L10 and A7(74) is the opal 
stop codon that is located close to the 3’ end of the nsP3-coding sequence of the 
latter (II, Table 1). However, the effect of the stop codon alone on SFV 
virulence is limited (175). Hence, the avirulence/ virulence determinants in 
nsP3 of SFV appear to be more complex. NsP3 has been shown to play a role in 
interactions with multiple host components (129, 132, 222). It is possible that 
different strains of SFV interact with different host factors or with the same host 
factors but with different efficiencies in a cell type/tissue-specific way, which in 
turn could result in contrasting phenotypes. It is also possible that the speed of 
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P123 processing (see 5.2.4) and the functions of nsP3 are linked: the two 
virulence determinants may represent different aspects of the same mechanism 
(pathway). The initial data concerning type I IFN induction in response to 
different SFV strains and recombinant viruses is consistent with this hypothesis 
(see 5.3).  
In addition to its rather enigmatic role in SFV virulence, we have described a 
previously unknown function of nsP3. The analysis of ns polyprotein pro-
cessing revealed a profound stabilization of nsP4 in viruses carrying a 
duplicated nsP3 region (II, Fig. 3C). This effect was not simply caused by the 
addition of an extra processing unit into the ns polyprotein of SFV, because the 
nsP4 of viruses carrying EGFP (or any other marker) between the nsP3 and 
nsP4 regions (219) is not stabilized. Individual molecules of nsP4 are known to 
be rapidly degraded (145), whereas, in formed RCs, the nsP4 appears to be 
stable. However, the mechanisms responsible for this stabilization have not 
been determined. Our data strongly suggest that nsP3 is actively involved in this 
phenomenon. The stabilization may occur via the inclusion of excessive 
amounts of nsP4 into complexes, which could be RCs or some other complexes 
of nsP3 and nsP4. Analyses of the composition of RCs made by wt SFV and by 
SFV carrying an extra copy of nsP3 are needed to ascertain whether or not this 
is the case. To achieve this goal, the methodology described in publication III 
could be applied. 
 
 
5.3. The role of the type I IFN response  
in SFV neurovirulence (unpublished) 
In the absence of type I IFN response, SFV infection is lethal regardless of the 
age of the host or strain of the virus (179). Thus, type I IFN is an essential 
component of the host response to viral infection. Viruses have evolved 
mechanisms to antagonize the production of and/or cellular response to type I 
IFN. The contrasting pathogenicity of A7(74) and L10 could depend on the 
different abilities of these viruses to induce (or to evade) type I IFN production, 
to interfere with the host type I IFN response, or to resist the antiviral effects of 
type I IFN.  
Previous studies with SINV have demonstrated that a determinant within the 
1/2 cleavage region is associated with slower ns polyprotein processing and 
delayed 26S sgRNA synthesis in the neurovirulent strain AR86. Consistently, 
accelerated processing and earlier expression from the viral 26S promoter are 
associated with the nonneurovirulent phenotype of SINV (93, 221). Additional 
characterization of this determinant demonstrated that the avirulent virus 
induces higher type I IFN production both in vivo and in vitro (94), which is 
probably because, unlike AR86, this mutant cannot suppress STAT1/STAT2 
activation in response to type I/type II IFN (151). Interestingly, this phenotype 
is not specific to the SINV AR86 because a similar mutation introduced into the 
13
50 
1/2 cleavage site of P1234 of RRV also leads to enhanced type I IFN induction 
(94). Thus, in the case of SINV AR86, pathogenicity correlates with effective 
suppression of the type I IFN response both in vivo and in vitro. However, this 
trend is not a general characteristic of all alphaviruses or even all strains of 
SINV. There are other determinants of neurovirulence in the E2 glycoproteins 
of SINV as well as in the 5’ UTR (223, 224) that are not associated with altered 
IFN production. The same is true for phenotypic differences between SFV4 and 
L10 (I). Finally, an opposite effect has been described in two recent papers. 
First, it was observed that neuroadapted SINV, which kills all C57BL/6 but not 
BALB/c mice, displayed higher levels of viral replication, higher levels of type 
I IFN, and slower viral clearance in susceptible mice. This finding strongly 
suggests that fatal encephalomyelitis in C57BL/6 mice is mediated by the 
immune response rather than being a direct result of viral infection (225). 
Second, it has been shown that neurovirulent SFV4 induces greater amounts of 
IFN-β than the avirulent VA7 strain (variant of A7(74)). In addition, SFV4 is 
less susceptible to the antiviral effect of type I IFN (191). Thus, enhanced 
neurovirulence can result either from the ability of the virus to suppress type I 
IFN production (as in the case of SINV AR86) or from its ability to induce 
excessive amounts of type I IFN, which can result in an immune-mediated 
pathology (as in the case of neuroadapted SINV in C57BL/6 mice). Therefore, 
it became important to analyze the ability of our constructed recombinant 
viruses (II) to induce the production of type I IFN.  
First, IFN-β production was analyzed in COP5 cells (murine fibroblasts with 
an intact IFN response). When the cells were infected with different re-
combinant viruses at an MOI of 0.1, no IFN-β production was observed at 12 h 
postinfection (data not shown). This indicated that all of the investigated viruses 
were capable of counteracting type I IFN production in the initially infected 
cells. However, at 24 h postinfection, IFN-β was readily detected (Fig. 7). This 
IFN was produced by cells infected by virus released from the initially infected 
cells. The same phenomenon has also been described for SINV. It has been 
proposed that very low, subprotective doses of IFN-β, which are produced by 
initially infected cells and do not induce the antiviral response in uninfected 
cells, have a very strong stimulatory effect on the ability of cells to express type 
I IFN and to activate IFN-stimulated genes during subsequent infection (226). 
We found that the virulent strain SFV6 induced the highest amount of IFN-β, 
whereas the avirulent A774wt induced much lower levels of IFN (Fig. 7), which 
is consistent with data from a previous study (191). However, no direct 
correlation between the virulence of different recombinant viruses and the 
amount of IFN-β produced in this experiment was evident. The only conclusion 
from these data is that all viruses harboring the A774wt backbone induce lower 
levels of IFN-β than viruses that possess the SFV6 backbone (Fig. 7). 
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Figure 7. Production of IFN-β by SFV infected cells. COP5 cells were infected at an 
MOI of 0.1 with wt and the indicated recombinant viruses. At 24 h postinfection the 
supernatants were gathered and the levels of IFN-β measured.  
 
The most likely explanation for the observed discrepancies is as follows. In this 
experiment, IFN-β was produced almost exclusively during secondary infection, 
in cells infected by virions released from the initially infected cells. This makes 
any standardization of the experimental conditions very difficult, since the 
magnitude of final IFN-β response depends on the following:  
- the MOI (a lower MOI results in a greater number of cells that can be 
infected by the new generation of virions);   
- the ability of different stocks of virus to suppress the production of minor 
quantities of IFN-β (part of this IFN may, for example, be produced by cells 
that become infected by defective viruses that are always present in any 
virus preparation), which prime uninfected cells;  
- the precise speed of viral replication/release: IFN-β production during 
secondary infection is not a synchronized event, it rather represents a self-
amplifying cascade, in which most of the IFN-β is produced by efficiently 
primed (but still susceptible to infection) cells;  
- the sensitivity of the virus to the antiviral effects of IFN: all (or almost all) 
IFN-β is produced by cells that have been previously exposed to IFN (albeit 
at very low concentrations); thus the spread of A774wt may be diminished 
due to type I IFN-dependent paracrine signaling (191).  
Taken together, this assay is not suitable to analyze the differences in type I IFN 
production using this panel of constructed recombinant viruses. 
Recently, our research team discovered a novel mechanism by which SFV 
induces type I IFN response (188). Briefly, type I IFN can be induced by SFV 
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replicase in the absence of replication-competent template RNA (Fig. 8A). This 
mechanism is highly relevant to natural SFV4 infection, and the large majority 
of type I IFN-inducing PAMP (pathogen-associated molecular pattern) RNAs 
that are produced in SFV4-infected cells originate via this pathway (188). 
Importantly, for the present study, this phenomenon allowed us to use an 
efficient and far more reliable test system in which type I IFN is produced in 
transfected cells (Fig. 8A). In addition, in this system the production of PAMP 
RNAs is not affected by the antiviral effects of type I IFN. Furthermore, the 
analysis allowed us to verify for the first time whether this novel pathway 
leading to type I IFN induction was relevant to the important biological pro-
perties of SFV. 
All of the analyzed replicases were roughly equivalent in their abilities to 
trigger the replication of the truncated SFV mini-genome (data not shown), 
which indicated that none of these replicases were defective. This finding is in 
agreement with data demonstrating that the corresponding viruses grow to 
similar titers (II, Fig. 5A, 6A). Then the experiment was conducted in the 
absence of replication-competent template, and the amounts of IFN-β released 
by transfected cells were measured. As shown in figure 8B, a perfect correlation 
between the in vivo phenotypes of the recombinant viruses and the ability of the 
corresponding replicases to induce IFN-β production in a replication-
independent manner was observed. The replicases of avirulent viruses (SFV6-
74-RE and A774wt) were poor inducers of IFN-β, while those of virulent ones 
induced moderate to high levels of IFN-β. Furthermore, perfect gradients of 
IFN-β production were observed for both replicase backbones:  
- SFV6 > SFV6-74 > SFV6-RE  > SFV6-74-RE, and  
- A774wt < A774wt-6 ≈ A774-HV < A774-6-HV. 
This finding strongly suggests that the neurovirulence of SFV has a clear 
similarity to that of neuroadapted SINV and that the ability of SFV to spread in 
the CNS of adult mice correlates with excessive induction of type I IFN. The 
spread of infection may be facilitated by the greater capacity of virulent SFV6 
to resist the antiviral effects of IFN. However, this supposition is doubtful 
because type I IFN tolerance-associated loci (most likely residing in nsP4) are 
distinct from the loci that are responsible for SFV neurovirulence (191). Thus, it 
is possible that virulent A774wt-6 and A774-HV still harbor an IFN-sensitive 
phenotype. Furthermore, as recombinant viruses grow to similar titers (II Fig. 
5A, 6A) it could be concluded that SFV neurovirulence is not associated with 
enhanced production of standard PAMP RNAs (dsRNA replication intermediates 
and negative strand RNAs with 5’ ppp groups). Instead, the enhanced spread of 
the virus and immunopathology appear to be triggered by the production of 
PAMP RNAs generated by SFV replicase through the use of cellular templates. 
Finally, this finding clearly demonstrates that two virulence determinants of 
SFV, which were identified in publication II, act via one and the same 
mechanism. Both slower processing of the 1/2 cleavage site and nsP3 of SFV6 
clearly increase the ability of the SFV replicase to trigger IFN-β production; 
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Figure 8. The ability of recombinant SFV replicases to induce IFN-β. A. Schematic 
representation of the experimental design. Cells are transfected with a plasmid encoding 
SFV replicase, which is transcribed by cellular machinery; resulting mRNA is translated 
to replicase proteins. The replicase is able to use cellular templates to produce short 
RNAs with 5’ ppp, which form duplexes with their templates. These nonclassical 
PAMP RNAs are recognized by RIG-I leading to induction of IFN-β, which can then be 
detected. B. COP5 cells were transfected with plasmid encoding either wt or re-
combinant SFV replicase. At 24 h posttransfection, the supernatants were gathered and 
the levels of IFN-β measured. Replicases corresponding to the viruses with an avirulent 
phenotype in mice are indicated by asterisks. 
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furthermore, the effects of these determinants are cumulative (Fig. 8B). 
Validation and assessment of these findings, including the precise roles of the 
pathogenesis determinants in the induction of IFN-β production, represent 
topics of further studies.  
It should also be noted that there are two main classes of cells in the CNS: 
nerve cells (neurons) and glial cells (e.g., oligodendrocytes, astrocytes). Avirulent 
strains such as A7(74) infect oligodendrocytes but display severely restricted 
replication in mature neurons. Virulent strains (e.g., SFV4, L10) infect both 
oligodendrocytes and neurons and spread rapidly throughout the brain. These two 
features of neurovirulence seem to depend on different determinants. In 
nonneuronal cells, increased virulence correlates with an elevated resistance to 
the antiviral effects if type I IFN. This is in agreement with previous findings 
demonstrating that the replication of A7(74) in type I IFN receptor-deficient mice 
increases dramatically in peripheral tissues and nonneuronal CNS cells but not in 
neurons (179). The restricted replication of avirulent strains such as A7(74) in 
neurons, however, appears to depend on the processing speed of the ns 
polyprotein and the sequence of nsP3, which together affect the ability to produce 
PAMP RNAs from cellular templates (Fig. 8B). Such PAMP RNAs are mostly 
recognized by RIG-I (188), and thus it is possible that not only type I IFN but 
also genes directly induced by activated RIG-I may contribute to the generation 
of conditions that permit the replication of SFV in mature neurons. 
These studies concentrated on characterizing the determinants responsible 
for the different in vivo phenotypes of SFV strains. A large amount of new 
knowledge was obtained, but further analyses (especially in vivo analyses) are 
needed to elucidate the importance and role of host defense mechanisms in 
determining the differences in SFV neurovirulence. Similarly, it will be 
intriguing to determine whether these findings apply to other alphaviruses. 
 
 
5.4. Magnetic fractionation and proteomic dissection 
provide a useful method to study the composition  
of SFV replication organelles (III) 
To fully comprehend the complexity of viral infection, it is important not to 
only examine the virus and host as separate entities but rather see the virus-
infected cell as a cooperative functional unit of infection. Alphaviruses encode 
only ten proteins, and therefore most steps in virus infection involve inter-
actions between relatively few viral components and much more complex pools 
of host factors. The differences between various strains of SFV are, on the one 
hand, caused by differences in their genomes, but, on the other hand, deter-
mined by the host factors and complex processes that occur in the host. There-
fore, it is important to also investigate these aspects of viral infection. Several 
studies investigating SINV have identified numerous factors that bind ns pro-
teins, and nsP2 of CHIKV has been shown to interact with a number of host 
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proteins. However, methods such as Y2H screening and immunoprecipitation 
have limitations because they do not differentiate between host proteins asso-
ciated with individual nsPs and those associated with RCs and replication orga-
nelles. Furthermore, cellular proteins do not necessarily need to interact with 
virus nsPs directly to affect replication. Hence, multiple alternative methods are 
needed to understand the complete picture of alphavirus-host interactions.  
 
5.4.1. Vesicles carrying functionally active RCs  
can be purified via magnetic enrichment 
In the present study, we introduced a new approach to identify host proteins that 
colocalize with mature RCs of SFV. The RCs of alphaviruses form on the 
plasma membrane and are then internalized via endocytosis (71, 72). For some 
alphaviruses, such as SFV, they finally localize to large vesicles of endolyso-
somal origin called CPV-Is (III, Fig. 1B). For other alphaviruses, for example 
CHIKV, most of the vesicles carrying RCs remain close to the plasma 
membrane and are smaller in size (75). This unique replication organelle bio-
genesis pathway, coupled with the specific features of SFV replication 
organelle formation, made it possible to apply a method that was originally used 
in studies of proteins involved in endocytosis (227) to isolate functional 
replication organelles of SFV. To the best of our knowledge, this is the first 
example of the use of such a method in studies of viral infection.  
The method involved feeding mock- or SFV4-infected cells with dextran-
covered magnetic nanoparticles, which were incorporated into lysosomes, per-
mitting the collection of these specific vesicles via magnetic isolation (III, Fig. 
2A). The obtained magnetic fractions were enriched for endolysosomes but 
largely devoid of plasma membrane and ER markers (III, Fig. 2C). The vesicles 
were shown to contain all of the ns proteins of SFV (III, Fig. 2C) in the form of 
functional RCs, evident from their maintained ability to synthesize RNA after 
isolation (III, Fig. 3A). This magnetic isolation possessed several advantages over 
ultracentrifugation-based separation: it was faster and did not damage the activity 
of RCs. The limitation of this method is that it can only be applied to study later 
stages of SFV infection, because CPV-Is are not formed immediately after virus 
entry. Mature alphavirus RCs only synthesize positive-strand RNAs, and there-
fore, purified replication organelles may not carry the specific host components 
that are important for early stages of infection, such as RNA template recruitment, 
cellular membrane remodeling, and viral negative-strand RNA synthesis. 
 
5.4.2. The proteome of magnetically isolated fractions can  
be characterized by using quantitative proteomics approach  
Prior to this study, the protein composition of SFV replication organelles 
(beyond the presence of viral proteins and lysosomal markers) was unknown. It 
is reasonable to assume that some host proteins are included in these structures 
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accidentally or because they are integral components of lysosomal membranes, 
while others are included (or excluded) due to specific virus-host interactions. 
To identify host proteins that are enriched or depleted in the magnetically 
purified fractions containing SFV replication organelles, a gel-free SILAC-
based (stable isotope labeling with amino acids in the cell culture) quantitative 
proteomics approach (228) was employed. This approach allows the detection 
of relative changes in the amounts of protein between different biological 
samples.  
In this study, heavy (labeled with heavy arginine and lysine) and light samples 
from SFV4-infected and uninfected cells (three biological replicates) were 
analyzed (III, Fig. 2B). Comparison of the protein compositions of the magneti-
cally isolated fractions produced a list of proteins that were overrepresented in 
the lysosomal membranes of infected cells (III, Table 1). We did not identify 
any proteins that were downregulated by a factor of 2.5 or more in samples 
containing SFV CPV-Is, most likely due to the co-purification of large amounts 
of normal endosomes (by rough estimation, approximately 50% of the total 
number of isolated vesicles did not contain viral RCs), making this approach 
unsuitable for the detection of proteins that were excluded from the replication 
organelles of the virus. In contrast, a number of proteins enriched in the fraction 
containing RCs were identified. Importantly, several of these proteins have 
previously been shown to associate with the alphavirus replicase using alter-
native methods. These include the RNA-binding proteins G3BP1, G3BP2, 
hnRNP C, hnRNP M, and hnRNP A1, which are known to interact with ns 
proteins or genomic and sgRNAs of SINV (131, 161, 162, 165), and hnRNP K, 
which has been shown to bind CHIKV nsP2 (167). Thus, the SILAC-based 
proteomics approach is suitable for identifying cellular proteins that colocalize 
and/or interact with alphavirus RCs.  
 
5.4.3. PCBP1, hnRNP M, hnRNP C, and  
hnRNP K affect alphavirus infection 
The obtained list of host factors included nearly 50 proteins that were not 
previously known to colocalize with alphavirus RCs and that are likely to be 
important for SFV replication (III, Table 1). These proteins belonged to dif-
ferent functionally connected clusters (III, Fig. 4), among which the cluster of 
RNA-interacting proteins was the most prominent. The impact of four of these 
RNA-binding proteins, PCBP1, hnRNP M, hnRNP C, and hnRNP K, on 
alphavirus infection was analyzed.  
In uninfected cells, PCBP1, hnRNP M, hnRNP C, and hnRNP K localize 
predominantly to the nucleus. Confocal microscopy analysis of infected cells 
showed that all four of these proteins colocalized with dsRNA, nsP3, and there-
fore, with the SFV RCs (III, Fig. 5 and Fig. 6). This confirmed that their relo-
calization during the late phase of SFV infection was not a random event. To 
analyze the functional significance of these proteins in alphavirus infection, 
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siRNA-mediated silencing experiments were conducted. Silencing of hnRNP C 
and hnRNP M increased SFV gene expression and replication (III, Fig. 7B, 8A, 
8B). Conversely, PCBP1 silencing reduced the synthesis of reporter proteins 
expressed both from genomic and sgRNAs of the SFV replicon but failed to 
affect or only minimally affected viral RNA synthesis and SFV growth in cell 
culture. Silencing of hnRNP K showed that this protein had little impact on the 
RNA synthesis and multiplication of SFV (III, Fig. 7B, 8A, 8B). 
Cellular factors may not affect the infection cycle of different alphaviruses 
in the same manner. Therefore, the importance of PCBP1, hnRNP M, hnRNP 
C, and hnRNP K in SINV and CHIKV infection was analyzed. Silencing of 
PCBP1, hnRNP C and hnRNP M had the same outcome as that observed in 
SFV-infected cells (III, Fig. 9). In contrast to SFV infection, during which it 
functioned as a repressor, hnRNP K was shown to function as an activator in 
CHIKV and SINV infection (III, Fig. 9), which is consistent with previous 
publications (165, 167). Thus, not all of the host proteins analyzed in the 
present study affected different alphaviruses similarly. The observation that the 
same host factor had contrasting effects on different viruses may reflect 
differences in the infection cycles of these viruses.  
As a next step, the magnetic fractionation and proteomic dissection method 
introduced in this study could be used to extract and analyze the composition of 
the replication organelles of cells infected with the previously constructed re-
combinant SFVs carrying duplicated nsP3 regions. This approach could be used 
to elucidate the role of nsP3 in the stabilization of nsP4. A comparison of RC-
containing fractions from cells infected with wt SFV6 and, for example, cells 
infected with SFV6-6/6 could shed light on the localization of excessive 
amounts of nsP4 and also reveal what other changes (if any) are caused by the 
duplication of the nsP3-encoding regions. It would also be interesting to 
determine whether different strains of SFV (avirulent and virulent) interact with 
different sets of host factors or whether the same host factors have different 
effects on these viruses, in the way hnRNP K has different effects in SINV, 
CHIKV and SFV infection. Finally, the applicability of the method is not 
restricted to the viruses used or developed during these studies. For example, 
SFV mutants that are unable to bind amphiphysins (129) or G3BP proteins 
(134) have recently been constructed. It would be interesting to determine if and 
how the loss of one interaction partner will affect the proteome of the 
alphavirus replication organelle. 
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6. CONCLUSIONS 
A7(74), L10, and SFV4 are the most thoroughly studied strains of SFV. A7(74) 
is considered to be avirulent because the infection in adult mice is asympto-
matic. In contrast, after i.c. or high-dose i.p. inoculation, L10 and SFV4 are both 
virulent and cause lethal encephalitis. However, following low-dose i.p. inocu-
lation, SFV4 is incapable of reaching the brain, and the infected animals sur-
vive. In the present study, biological stocks of A7(74) and L10 strains of known 
provenance were sequenced, and two new consensus clones, A774wt and 
SFV6, were constructed. These and the molecular clone of SFV4 were used to 
study the determinants and mechanism(s) of SFV neurovirulence. The fol-
lowing conclusions were made based on the data, obtained in these studies: 
First, a comparison of the consensus sequence of L10 with the published 
sequence of SFV4 revealed that the latter contains six nonsynonymous changes, 
which may result from different passage histories and represent adaptations to 
the cell culture and/or i.c. passaging of the virus stock used to build the SFV4 
molecular clone. The different phenotypes of SFV4 and SFV6 are caused by 
differences in a single amino acid residue located at position 162 of the E2 
protein. A negatively charged glutamic acid residue (as in SFV6) increased the 
viral load in mouse blood and enhanced neuroinvasion and virulence. A 
positively charged lysine at the same position (as in SFV4) was responsible for 
the low viral load in the blood. However, this lysine residue facilitated the 
ability of the virus to cross an in vitro BBB model and to replicate in the mouse 
brain following i.c. infection. These properties correlated with the ability of the 
corresponding virions to bind GAGs. These findings led to the conclusion that a 
positive charge at position 162 (or 247) of E2 facilitates the binding of SFV4 
virions to HS. This results in rapid clearance of virus from the blood and lower 
viremia, which in turn prevents the entry of the virus into the CNS. 
 Second, the determinants responsible for the different neurovirulence of 
A7(74) and L10 were investigated. A previously available molecular clone of 
A7(74) was found to have a defect resulting from a change in a single amino 
acid residue in nsP3; by repairing this defect, a highly infectious consensus 
clone, A774wt, was obtained. Using viruses with swapped or duplicated nsP3 
regions revealed that neurovirulence is the dominant function of nsP3: all of the 
viruses expressing SFV6 nsP3 were virulent. The in vivo phenotype was also 
dependent on the fine-tuned functions of ns proteins, such as the basic protease 
activity of nsP2 and the efficiency of P123 processing. The presence of A774wt 
nsP3 (or rather the absence of SFV6 nsP3) and rapid cleavage of ns polyprotein 
at the 1/2 site were both required for the avirulent phenotype. Both slower 
processing of the 1/2 cleavage site or the presence of SFV6 nsP3 enhanced the 
ability of the virus replicases to produce PAMP RNAs from cellular templates 
and thereby induce a strong type I IFN response. Thus, the ability of SFV to 
spread in the CNS of adult mice correlates with the capacity of the virus to 
cause excessive induction of type I IFN, suggesting a link between SFV 
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neurovirulence and immunopathology. In addition, a novel function of nsP3, 
involvement in the stabilization of nsP4, was identified. 
The finding that biological differences between SFV strains are determined, 
at least in part, by virus-host interactions and complex processes that occur in 
the host (e.g., the IFN response) emphasizes the need to identify and analyze 
host factors that are involved in alphavirus infection. Thus, a novel approach to 
determine the host proteins that colocalize with mature RCs of SFV was devel-
oped. This approach is based on feeding cells dextran-covered magnetic nano-
particles and subsequently collecting lysosomal vesicles harboring RCs via 
magnetic isolation. We paired this technique with SILAC-based quantitative 
proteomics and generated an extensive list of host factors associated with SFV 
RCs. Further characterization of four of these factors confirmed their sig-
nificance in SFV infection. Interestingly, three of these factors were found to be 
antiviral, while only one was confirmed to be proviral. 
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SUMMARY IN ESTONIAN 
Samm lähemale mõistmaks Semliki Forest viiruse 
neurovirulentsust 
Semliki Forest viirus (SFV) on positiivse polaarsusega RNA genoomiga viirus, 
mis kuulub alfaviiruste perekonda sugukonnas Togaviridae. Alfaviiruste seas 
leidub mitmeid inimese ja loomade patogeene, mille poolt põhjustatavad haigu-
sed varieeruvad külmetuse sarnaste sümptomitega tõvest aastaid kestva artriidi 
või fataalse entsefaliidini. Seega kujutab alfaviiruste uurimine endast olulist 
valdkonda. SFV on inimesele suhteliselt ohutute laboratoorsete tüvede olemas-
olu tõttu antud perekonnas üheks enim uuritud esindajaks; seda viirust on laial-
daselt kasutatud nii geenitehnoloogia süsteemina kui ka mudelobjektina viirus-
liku entsefaliidiga kaasneva patogeneesi uurimisel.  
Kõige põhjalikumalt uuritud SFV tüvedeks on A7(74), SFV4 ja L10. A7(74) 
on avirulentne tüvi, sest see põhjustab täiskasvanud hiires asümptomaatilist 
infektsiooni. SFV4 ja L10 on aga  virulentsed tüved, sest otse ajju või kõrge 
doosiga kõhuõõnde süstituna põhjustavad nad hiirtel surmaga lõppevat entsefa-
liiti. Kui aga kõhuõõnde süstimiseks kasutada bioloogiliselt mõtestatud (samas 
suurusjärgus, kui seda sisestavad viirust edasikandvad sääsed) kogust viirust, 
siis SFV4 ei jõua ajju ning nakatatud hiired jäävad ellu. Käesoleva uurimistöö 
üldeesmärgiks oli uurida tegureid ja mehhanisme, mis vastutavad nende tüvede 
erineva neurovirulentsuse eest.  
Esimeseks eesmärgiks oli luua L10 tüvele vastav konsensuskloon ning ana-
lüüsida SFV4 ja L10 erinevaid fenotüüpe põhjustavaid molekulaarseid determi-
nante ja mehhanisme. Tehtud uurimused näitasid, et SFV4 ja L10 vahelised eri-
nevused hiires on tingitud viiruse ümbrisevalgu aminohapete laengutest. Nega-
tiivse laenguga glutamiinhappejäägid E2 valgu teatud positsioonides võimal-
davad viirusel põhjustada kõrget vireemiat. Kõrge vireemia on omakorda eeldu-
seks viiruse jõudmisel ajju ning seetõttu on E2 valgus negatiivse laenguga 
aminohappejääke sisaldavad viirused (nagu L10) neuroinvasiivsed ning viru-
lentsed. Positiivse laenguga lüsiinijäägid vastavates E2 valgu positioonides 
vastutavad madala vireemia eest, mistõttu ei suuda sellised viirused (nagu 
SFV4) ajju siseneda ega entsefaliiti põhjustada. E2 valgul on oluline roll viiruse 
seondumisel peremehe rakkudele. Me näitasime, et positiivse laenguga lüsiini-
jäägid E2 valgus soodustavad küll viiruse seondumist koekultuuri rakkudele, 
kuid põhjustavad in vivo tingimustes SFV4 virionide efektiivse seostumise 
heparaansulfaadiga, mis vähendab viiruse taset veres ja selle kaudu võimekust 
ajju siseneda.   
Järgnevaks eesmärgiks oli kasutada meie loodud A7(74) ja L10 tüvede kon-
sensusjärjestustele vastavaid rekombinantseid viirusi, et heita valgust nende 
tüvede vahelisi fenotüübilisi erinevusi põhjustavatele molekulaarsetele teguritele. 
Saadud andmed näitasid, et erinevused A7(74) ja L10 neurovirulentsuses on 
tingitud erinevustest viiruse mittestruktuurse liitvalgu proteolüütilise lõikamise 
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kiiruses ning mittestruktuurse valgu 3 (nsP3) järjestuses. Saadud tulemused 
näitavad, et neurovirulentsuse põhjustamisel on virulentse tüve nsP3 valgul 
dominantne funktsioon. A7(74) nsP3 valk (või pigem L10 nsP3 valgu puudu-
mine) ja mittestruktuurse liitvalgu 1/2 lõikamisjärjestuse kiire protsessimine 
vastutavad avirulentse in vivo fenotüübi eest. Liitvalgu 1/2 lõikamisjärjestuse 
aeglane protsessimine või L10 nsP3 valgu olemasolu suurendavad SFV repli-
kaasi võimet sünteesida ebaharilikke PAMP RNA-sid, kasutades matriitsina raku 
RNA-sid, ja see omakorda põhjustab tugevat interferoonvastust. Seega, SFV 
tüvede erinev suutlikkus täiskasvanud hiire ajus levida korreleerub siin viiruste 
erineva võimega indutseerida interferooni tootmist; see viitab seosele SFV 
neurovirulentsuse ja immunopatoloogia vahel.  
Üheks uurimustöö alameesmärgiks oli analüüsida SFV replikatsioonikomp-
leksidega seonduvaid valke, saamaks paremat ülevaadet alfaviiruse ja peremehe 
vahel esinevatest keerulistest interaktsioonidest. Selleks arendati käesolevas 
uurimistöös välja uus lähenemine, mis põhineb rakkude söötmisel dekstraaniga 
kaetud magneetiliste nanopartiklitega ja järgneval viiruse replikatsioonikomp-
lekse sisaldavate lüsosoomide magneetilisel eraldamisel. Mitteradioaktiivsel 
isotoopmärgistusel põhineva kvantitatiivse proteoomika kasutamine võimaldas 
meil koostada põhjaliku nimekirja SFV replikatsioonikompleksidega seostu-
vatest rakulistest valkudest. Nelja sellesse nimekirja kuuluva valgu edasine 
põhjalikum analüüs kinnitas nende olulisust SFV infektsioonis ja seega ka 
uudse metoodika usaldusväärsust. Järgneva sammuna võiks antud meetodit 
kasutada erineva virulentsusega SFV tüvede uurimiseks. Oleks huvitav teada, 
kas erinevad SFV tüved seostuvad erinevate peremehe poolsete valkudega või 
mõjutavad samad peremehe valgud erinevaid SFV tüvesid erinevalt. See oma-
korda avardaks veelgi meie arusaamist SFV patogeensuse põhjustest ja mehha-
nismidest.  
Käesoleva uurimistöö käigus saadud tulemused aitavad ühelt poolt paremini 
mõista SFV neurovirulentsust, lisaks sellele on mudelviiruse uurimisel kasu-
tatud meetode ja avastatud seaduspärasusi võimalik rakendada ka inimesele oht-
like alfaviiruste mõistmiseks.  
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